

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 June 2006 (08.06.2006)

PCT

(10) International Publication Number
WO 2006/059945 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) **A61P 9/10** (2006.01)
A61K 31/47 (2006.01) **C07D 215/14** (2006.01)
A61K 31/4709 (2006.01) **C07D 215/38** (2006.01)
A61K 31/496 (2006.01) **C07D 401/06** (2006.01)
A61P 11/06 (2006.01) **C07D 401/14** (2006.01)
A61P 19/02 (2006.01) **C07D 413/06** (2006.01)
A61P 19/08 (2006.01)

AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2005/001782

(22) International Filing Date:

28 November 2005 (28.11.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0402925-2 30 November 2004 (30.11.2004) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EVANS, Richard** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **FORD, Rhonan** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **THOMPSON, Toby** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **WILLIS, Paul** [GB/GB];


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS



(I)

(57) Abstract: The invention provides compounds of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, in which A, n, p, q, R¹, R², R³ and R⁴ are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.

WO 2006/059945 A1

Novel adamantane-substituted quinoline derivatives
as P2X₇ receptor inhibitors.

The present invention relates to adamantane derivatives, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical
5 compositions, and their use in therapy.


The P2X₇ receptor (previously known as P2Z receptor), which is a ligand-gated ion channel, is present on a variety of cell types, largely those known to be involved in the inflammatory/immune process, specifically, macrophages, mast cells and lymphocytes
10 (T and B). Activation of the P2X₇ receptor by extracellular nucleotides, in particular adenosine triphosphate, leads to the release of interleukin-1 β (IL-1 β) and giant cell formation (macrophages/microglial cells), degranulation (mast cells) and proliferation (T cells) and apoptosis and L-selectin shedding (lymphocytes). P2X₇ receptors are also located on antigen-presenting cells (APC), keratinocytes, salivary acinar cells (parotid
15 cells), hepatocytes and mesangial cells.

It would be desirable to make compounds effective as P2X₇ receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases, in the aetiologies of which the P2X₇ receptor may play a role.

20

The present invention provides a new class of adamantyl-containing P2X₇ antagonist which comprise a substituted quinoline moiety. These novel compounds display attractive properties for use as P2X₇ receptor antagonists in the treatment of inflammatory, immune or cardiovascular diseases. Whilst adamantyl-containing P2X₇ antagonists have been
25 described previously, for example in WO 99/ 29661, WO 99/29660, WO 00/61569 and WO 03/080579, prior to the present invention there had been no suggestion that a compound comprising the substituted quinoline moiety of the present invention would make an effective P2X₇ antagonist. Whilst WO 03/080579 does describe some quinoline-containing compounds, it does not teach the use of a quinoline moiety bearing the
30 substituents specified in the present invention.

In accordance with the present invention, there is therefore provided a compound of formula



or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, wherein n represents 1, 2 or 3;

each R^1 independently represents hydrogen, hydroxy or a halogen;

A is $C(O)NH$ or $NHC(O)$;

p is 0, 1 or 2;

each R^2 independently represents halogen or C_{1-6} alkyl optionally substituted by at least one substituent independently selected from hydroxyl, halogen and C_{1-6} alkoxy;

q is 0, 1 or 2;

each R^4 independently represents halogen or C_{1-6} alkyl optionally substituted by at least one substituent independently selected from hydroxyl, halogen and C_{1-6} alkoxy;

R^3 represents a group Y^1R^6 or Z^1R^{10} ;

R^6 represents a group R^8 or a 4- to 9-membered carbocyclic or heterocyclic ring, which carbocyclic or heterocyclic ring is substituted by at least one substituent independently selected from Y^2R^9 and Z^2R^{11} , and which 4- to 9-membered carbocyclic or heterocyclic

ring may further be optionally substituted by at least one substituent independently selected from halogen, hydroxyl, C_{1-6} alkoxy, C_{1-6} alkyl, phenyl and a 5- to 6-membered

heteroaromatic ring, which C_{1-6} alkyl, phenyl or 5- to 6-membered heteroaromatic ring may

be optionally substituted by at least one substituent selected from halogen, hydroxyl and C_{1-6} alkoxy;

R^8 and R^9 each independently represent tetrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl or a 5- to 6-membered heterocyclic ring comprising from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, which heterocyclic ring is substituted by at least one substituent selected from hydroxyl, =O and =S, and which heterocyclic ring may further be optionally substituted by at least one substituent selected from halogen, nitro, amino, cyano, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl and a C_{1-6} alkyl group which C_{1-6} alkyl group can be optionally substituted by at least one substituent selected from halogen, hydroxyl and amino;

10

R^{10} and R^{11} each independently represent carboxyl, C_{1-6} alkylsulphonylaminocarbonyl $C(O)NHOH$ or NHR^{12} ; R^{12} represents CN, C_{1-6} alkylsulphonyl, C_{1-6} alkylcarbonyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylaminosulphonyl or (di)- C_{1-6} alkylaminosulphonyl;

15

Y^1 and Y^2 each independently represent a bond, O, $S(O)_{0-2}$, $NR^7C(O)$, $C(O)NR^7$, SO_2NR^7 , NR^7SO_2 , $>NR^7$, $O(CH_2)_{1-6}$, $S(O)_{0-2}(CH_2)_{1-6}$, $NR^7(CH_2)_{1-6}$, $(CH_2)_{1-3}O(CH_2)_{1-3}$, $(CH_2)_{1-3}S(O)_{0-2}(CH_2)_{1-3}$, $(CH_2)_{1-3}NR^7(CH_2)_{1-3}$, $(CH_2)_{1-3}NR^7C(O)(CH_2)_{0-3}$, $(CH_2)_{1-3}C(O)NR^7(CH_2)_{0-3}$, $S(O)_{0-2}(CH_2)_{1-6}NR^7$ or a C_{1-6} alkylene which C_{1-6} alkylene can be optionally substituted by at least one substituent independently selected from hydroxyl, halogen and C_{1-6} alkoxy;

20

Z^1 and Z^2 each independently represent a bond, $O(CH_2)_{1-6}$, $S(O)_{0-2}(CH_2)_{1-6}$, $NR^7(CH_2)_{1-6}$, $(CH_2)_{1-3}O(CH_2)_{1-3}$, $(CH_2)_{1-3}S(O)_{0-2}(CH_2)_{1-3}$, $(CH_2)_{1-3}NR^7(CH_2)_{1-3}$, $(CH_2)_{1-3}NR^7C(O)(CH_2)_{1-3}$, $(CH_2)_{1-3}C(O)NR^7(CH_2)_{1-3}$ or a C_{1-6} alkylene which C_{1-6} alkylene can be optionally substituted by at least one substituent independently selected from hydroxyl, halogen and C_{1-6} alkoxy; and

25

each R^7 independently represents hydrogen or a C_{1-6} alkyl group which can be optionally substituted by at least one substituent independently selected from hydroxyl, halogen and C_{1-6} alkoxy;

30

with the provisos that:-

- (a) when R^3 represents Y^1R^6 and Y^1 represents $NR^7(CH_2)_{1-6}$, $S(CH_2)_{1-6}$, $O(CH_2)_{1-6}$ or an optionally substituted C_{1-6} alkylene, then R^6 does not represent oxopyrrolidinyl;
- (b) when R^3 represents Z^1R^{10} and Z^1 represents $(CH_2)_{1-3}NR^7(CH_2)_{1-3}$, then R^{10} does not represent carboxyl;
- 5 (c) when R^3 represents Y^1R^6 and Y^1 represents $(CH_2)_{1-3}NR^7(CH_2)_{1-3}$ and R^6 represents a group R^8 , then R^8 does not represent a 5- to 6-membered heterocyclic ring substituted by hydroxyl or =O;
- (d) when R^3 represents Y^1R^6 and Y^1 represents $(CH_2)_{1-3}NR^7(CH_2)_{1-3}$ and R^6 represents a 4- to 9-membered carbocyclic or heterocyclic ring substituted by Z^2R^{11} and Z^2 represents a bond, then R^{11} does not represent carboxyl;
- 10 (e) when R^3 represents Y^1R^6 and Y^1 represents $NR^7(CH_2)_{1-6}$, $S(CH_2)_{1-6}$, $O(CH_2)_{1-6}$ or an optionally substituted C_{1-6} alkylene and R^6 represents phenyl substituted by Z^2R^{11} and Z^2 represents a bond, then R^{11} does not represent C_{1-6} alkylsulphonylamino;
- (f) when R^3 represents Z^1R^{10} and Z^1 represents $O(CH_2)_{1-6}$, $S(CH_2)_{1-6}$, $NR^7(CH_2)_{1-6}$ or an optionally substituted C_{1-6} alkylene and R^{10} represents NHR^{12} , then R^{12} does not represent C_{1-6} alkylcarbonyl; and
- 15 (g) the compound is not selected from tert-butyl 1-{5-[(1-adamantylacetyl)amino]-6-methylquinolin-2-yl}piperidin-4-ylcarbamate and tert-butyl (3S)-1-{5-[(1-adamantylacetyl)amino]-6-methylquinolin-2-yl}pyrrolidin-3-ylcarbamate.

20

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.

25

It will be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present invention encompasses all such solvated forms.

30

In the context of the present specification, a "Carbocyclic" ring is an unsaturated, saturated or partially saturated mono- or bicyclic ring, containing only carbon ring atoms, and may

have aliphatic or aromatic properties. A "Heterocyclic" ring is an unsaturated, saturated or partially saturated mono- or bicyclic ring, at least one atom of which is a heteroatom selected from oxygen, sulphur or nitrogen, and may have aliphatic or aromatic properties. The expression "Heteroaromatic" denotes aromatic rings, at least one atom of which is a heteroatom selected from oxygen, sulphur or nitrogen. Unless otherwise indicated an alkyl group may be linear or branched.

In an embodiment of the invention, n represents 1.

10 In an embodiment of the invention, each R^1 independently represents a hydrogen atom.

In an embodiment of the invention, A represents $C(O)NH$. In an alternative embodiment of the invention, A represents $NH(CO)$.

15 In an embodiment of the invention, p is 0 or 1.

Each R^2 independently represents halogen (e.g. chlorine, fluorine, bromine or iodine) or C_{1-6} , preferably C_{1-4} , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. zero, one, two or three) independently selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C_{1-6} , preferably C_{1-4} , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy).

In an embodiment of the invention, each R^2 independently represents halogen or C_{1-4} alkyl.

25

In an embodiment of the invention, q is 0 or 1.

Each R^4 independently represents halogen (e.g. chlorine, fluorine, bromine or iodine) or C_{1-6} , preferably C_{1-4} , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. zero, one,

30

two or three) independently selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C₁₋₆, preferably C₁₋₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy).

5 In an embodiment of the invention, each R⁴ independently represents halogen or C₁₋₄ alkyl.

R⁶ represents a group R⁸ or a 4- to 9-membered carbocyclic or heterocyclic ring, which carbocyclic or heterocyclic ring is substituted by at least one substituent (e.g. one or two) independently selected from Y²R⁹ and Z²R¹¹, and which 4- to 9-membered carbocyclic or
10 heterocyclic ring may further be optionally substituted by at least one substituent (e.g. zero, one or two) independently selected from halogen (e.g. chlorine, fluorine, bromine or iodine), hydroxyl, C₁₋₆, preferably C₁₋₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C₁₋₆, preferably C₁₋₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), phenyl and a 5- to 6-membered heteroaromatic
15 ring, which C₁₋₆ alkyl, phenyl or 5- to 6-membered heteroaromatic ring may be optionally substituted by at least one substituent (e.g. zero, one, two or three) selected from halogen (e.g. chlorine, fluorine, bromine or iodine), hydroxyl and C₁₋₆, preferably C₁₋₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy).

20 When R⁶ represents a 4- to 9-membered carbocyclic ring, examples of carbocyclic rings include cyclobutyl, cyclopentyl, cyclohexyl and phenyl.

In an embodiment of the invention, R⁶ represents phenyl. In a further aspect of this embodiment the phenyl group is substituted with a group Z²R¹¹, wherein Z² represents a
25 bond or a C₁₋₆ alkylene group and R¹¹ represents carboxyl.

When R⁶ represents a 4- to 9-membered heterocyclic ring, examples of heterocyclic rings are rings containing from 1 to 3, or 1 to 2, heteroatoms selected from nitrogen, oxygen and sulphur.

In an embodiment of the invention, R⁶ represents an aromatic 5- to 8-membered heterocyclic ring containing from 1 to 3, or 1 to 2, heteroatoms selected from nitrogen, oxygen and sulphur. Examples of aromatic heterocyclic rings according to this embodiment include pyridinyl, pyridazinyl, pyrizinyl, pyrimidyl, pyrazolyl.

5

In an embodiment of the invention, R⁶ represents an aliphatic 5- to 8-membered heterocyclic ring containing one nitrogen atom and optionally one further heteroatom selected from nitrogen and oxygen. Examples of heterocyclic rings according to this embodiment include pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, homopiperidinyl and azabicyclo[3.1.0]hexanyl.

10

R⁸ and R⁹ each independently represent tetrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl or a 5- to 6-membered heterocyclic ring comprising from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, which heterocyclic ring is substituted by at least one substituent (e.g. zero, one, two or three) selected from hydroxyl, =O and =S, and which heterocyclic ring may further be optionally substituted by at least one substituent (e.g. zero, one or two) selected from halogen (e.g. chlorine, fluorine, bromine or iodine), nitro, amino, cyano, C₁₋₆, preferably C₁₋₄, alkylsulphonyl (e.g. MeSO₂- or EtSO₂-), C₁₋₆, preferably C₁₋₄, alkoxy carbonyl (e.g. methoxy-, ethoxy-, n-propoxy-, n-butoxy-, n-pentoxy- or n-hexoxycarbonyl), and a C₁₋₆, preferably C₁₋₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) group which C₁₋₆ alkyl group can be optionally substituted by at least one substituent (e.g. zero, one, two or three) selected from halogen (e.g. chlorine, fluorine, bromine or iodine), hydroxyl and amino.

15

20


When R⁸ and R⁹ each independently represent a 5- to 6-membered heterocyclic ring, nitrogen heteroatoms in the heterocyclic ring may carry hydroxyl substituents and sulphur atoms in the ring may be in the form of S, SO (i.e. carrying one =O substituent) or SO₂ (i.e. carrying two =O substituents).

25


Where R⁹ or R¹⁰ represents a 5- to 6-membered heterocyclic ring comprising from 1-4 heteroatoms independently selected from nitrogen, oxygen and sulphur, which heterocyclic

30

ring is substituted by at least one substituent selected from hydroxyl, =O and =S, examples include:



- 5 In an embodiment of the invention, R^8 and R^9 each independently tetrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl,



- R^{10} and R^{11} each independently represent carboxyl, C_{1-6} alkylsulphonylaminocarbonyl (e.g. $MeSO_2NHCO-$, or $EtSO_2NHCO-$), $C(O)NHOH$, NHR^{12} ; R^{12} represents CN , C_{1-6} , preferably C_{1-4} , alkylsulphonyl (e.g. $MeSO_2-$ or $EtSO_2-$), C_{1-6} , preferably C_{1-4} , alkylcarbonyl (e.g. methyl-, ethyl-, n-propyl-, n-butyl-, n-pentyl- or n-hexylcarbonyl), C_{1-6} , preferably C_{1-4} , alkoxycarbonyl (e.g. methoxy-, ethoxy-, n-propoxy-, n-butoxy-, n-pentoxy- or n-hexoxycarbonyl), C_{1-6} , preferably C_{1-4} , alkylaminosulphonyl (e.g. $MeNHSO_2$ or $EtNHSO_2-$), or (di)- C_{1-6} , preferably C_{1-4} , alkylaminosulphonyl (e.g. Me_2NSO_2- or Et_2NSO_2- or $EtMeNSO_2-$).

In an embodiment of the invention, R^{10} and R^{11} each independently represent carboxyl, C_{1-6} alkylsulphonylaminocarbonyl or $C(O)NHOH$.

In another embodiment of the invention, R^{10} and R^{11} each independently represent carboxyl.

In an embodiment of the invention, Y^1 and Y^2 each independently represent a bond, O,
 5 $S(O)_{0-2}$, $NR^7C(O)$, $C(O)NR^7$, SO_2NR^7 , NR^7SO_2 , $>NR^7$, $O(CH_2)_{1-6}$, $S(O)_{0-2}(CH_2)_{1-6}$,
 $NR^7(CH_2)_{1-6}$, $(CH_2)_{1-3}O(CH_2)_{1-3}$, $(CH_2)_{1-3}S(O)_{0-2}(CH_2)_{1-3}$, $(CH_2)_{1-3}NR^7C(O)(CH_2)_{0-3}$,
 $(CH_2)_{1-3}C(O)NR^7(CH_2)_{0-3}$, $S(O)_{0-2}(CH_2)_{1-6}NR^7$ or a C_{1-6} , preferably C_{1-4} , alkylene group
 which C_{1-6} alkylene can be optionally substituted by at least one substituent (e.g. zero, one,
 two or three) independently selected from hydroxyl, halogen (e.g. chlorine, fluorine,
 10 bromine or iodine), and C_{1-6} , preferably C_{1-4} , alkoxy (e.g. methoxy, ethoxy, n-propoxy or
 n-butoxy).

In another embodiment of the invention, Y^1 and Y^2 each independently represent a bond,
 O, $S(O)_{0-2}$, $>NR^7$, $O(CH_2)_{1-6}$, $NR^7(CH_2)_{1-6}$ or a C_{1-6} alkylene.

15


In an embodiment of the invention, Z^1 and Z^2 each independently represent a bond,
 $O(CH_2)_{1-6}$, $S(O)_{0-2}(CH_2)_{1-6}$, $NR^7(CH_2)_{1-6}$, $(CH_2)_{1-3}O(CH_2)_{1-3}$, $(CH_2)_{1-3}S(O)_{0-2}(CH_2)_{1-3}$,
 $(CH_2)_{1-3}NR^7(CH_2)_{1-3}$, $(CH_2)_{1-3}NR^7C(O)(CH_2)_{1-3}$, $(CH_2)_{1-3}C(O)NR^7(CH_2)_{1-3}$ or a C_{1-6} ,
 preferably C_{1-4} , alkylene group which C_{1-6} alkylene can be optionally substituted by at
 20 least one substituent (e.g. zero, one, two or three) independently selected from hydroxyl,
 halogen (e.g. chlorine, fluorine, bromine or iodine), and C_{1-6} , preferably C_{1-4} , alkoxy (e.g.
 methoxy, ethoxy, n-propoxy or n-butoxy).

In another embodiment of the invention Z^1 and Z^2 each independently represent a bond,
 25 $O(CH_2)_{1-6}$, $NR^7(CH_2)_{1-6}$ or a C_{1-6} alkylene.

Each R^7 independently represents a hydrogen atom or a C_{1-6} , preferably C_{1-4} , alkyl (e.g.
 methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) group
 which can be optionally substituted by at least one substituent (e.g. zero, one, two or three)
 30 independently selected from hydroxyl, halogen (e.g. fluorine, chlorine, bromine or iodine)


and C₁₋₆, preferably C₁₋₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy, n-butoxy, n-pentoxo or n-hexoxy).

An embodiment of the invention provides a compound of formula



or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, wherein A, n, R¹, R² and R³ are as defined in formula (I).

In an embodiment of the invention, R³ represents a group Y¹R⁶. In a further aspect of this embodiment, Y¹ represents a bond or a C₁₋₆ alkylene and R⁶ represents a group R⁸ or a 4- to 9- membered heterocyclic ring substituted by at least one substituent selected from Y²R⁹ and Z²R¹¹, which 4- to 9- membered heterocyclic ring can further be optionally substituted by a substituent selected from halogen, hydroxyl, C₁₋₄ alkyl and phenyl. In a still further aspect of this embodiment, Z² represents a bond, NR⁷(CH₂)₁₋₆ or a C₁₋₆ alkylene group and R¹¹ represents carboxyl, C₁₋₆ alkylsulfonylaminocarbonyl or C(O)NHOH. In another aspect of this embodiment, Y² represents a bond, S(O)₀₋₂, NR⁷(CH₂)₁₋₆ or a C₁₋₆ alkylene group, and R⁹ represents tetrazolyl, 1,2,3- triazolyl, 1,2,4-triazolyl,



In another embodiment of the invention, R^3 represents a group Y^1R^6 wherein Y^1 represents a bond.

5

In a further embodiment of the invention, there is provided a subset of compounds of formula (I) and pharmaceutically acceptable salts or *in vivo* hydrolysable esters thereof, wherein

n represents 1;

10

each R^1 independently represents hydrogen;

A is $C(O)NH$ or $NHC(O)$;

p is 0 or 1;

each R^2 independently represents halogen or C_{1-4} alkyl;

q is 0 or 1;

15

each R^4 independently represents halogen or C_{1-4} alkyl;

R^3 represents a group Y^1R^6 ;

R^6 represents a group R^8 or a 4- to 9-membered carbocyclic or heterocyclic ring, which carbocyclic or heterocyclic ring is substituted by at least one substituent independently selected from Y^2R^9 and Z^2R^{11} , and which 4- to 9-membered carbocyclic or heterocyclic

20

ring may further be optionally substituted by at least one substituent independently selected from halogen, hydroxyl, C_{1-4} alkyl and phenyl;

R^8 and R^9 each independently represent tetrazolyl, 1,2,3- triazolyl, 1,2,4-triazolyl, or a 5- to 6-membered heterocyclic ring comprising from 1 to 4 heteroatoms

independently selected from nitrogen, oxygen and sulphur, which heterocyclic ring is

25

substituted by at least one substituent selected from hydroxyl, $=O$ and $=S$;

R^{11} represents carboxyl, C_{1-6} alkylsulphonylaminocarbonyl or $C(O)NHOH$;

Y^1 and Y^2 each independently represent a bond, O , $S(O)_{0-2}$, $>NR^7$, $O(CH_2)_{1-6}$, $NR^7(CH_2)_{1-6}$ or a C_{1-6} alkylene;

Z^2 represents a bond, $O(CH_2)_{1-6}$, $NR^7(CH_2)_{1-6}$ or a C_{1-6} alkylene; and each R^7 independently represents hydrogen or a C_{1-4} alkyl group; subject to proviso (a) of formula (I).

5 In a still further embodiment of the invention, there is provided a subset of compounds of formula (I) and pharmaceutically acceptable salts or *in vivo* hydrolysable esters thereof, wherein

n represents 1;

each R^1 independently represents hydrogen;

10 A is $C(O)NH$ or $NHC(O)$;

p is 0 or 1;

each R^2 independently represents halogen or C_{1-4} alkyl;

q is 0 or 1;

each R^4 independently represents halogen or C_{1-4} alkyl;

15 R^3 represents a group Y^1R^6 ;

R^6 represents a cyclic group selected from phenyl, pyridinyl or a 5- to 8-membered heterocyclic ring containing one nitrogen atom and optionally one further heteroatom selected from nitrogen and oxygen (e.g. pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, homopiperidinyl and azabicyclo[3.1.0]hexanyl), which cyclic group R^6 is substituted by at least one substituent Z^2R^{11} , and which cyclic group R^6 may further be optionally substituted by at least one substituent independently selected from hydroxyl, C_{1-4} alkyl and phenyl;

20 R^{11} represents carboxyl, C_{1-6} alkylsulphonylaminocarbonyl or $C(O)NHOH$;

Y^1 represents a bond;

25 Z^2 represents a bond, $O(CH_2)_{1-6}$, $NR^7(CH_2)_{1-6}$ or a C_{1-6} alkylene; and

R^7 represents hydrogen or a C_{1-4} alkyl group.

Pharmaceutically acceptable salts of a compound of formula (I) include, but are not limited to, base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, *N*-methylpiperidine, *N*-ethylpiperidine, procaine, 30 dibenzylamine, *N,N*-dibenzylethylamine or amino acids for example lysine. In another

aspect, where the compound is sufficiently basic, suitable salts include acid addition salts such as methanesulphonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically acceptable salt is a hydrochloride or sodium salt.

An *in vivo* hydrolysable (or cleavable) ester of a compound of formula (I) that contains a carboxyl or a hydroxyl group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxyl include C₁₋₄alkyl esters, for example, methyl; C₁₋₆alkoxymethyl esters, for example, methoxymethyl; C₁₋₆alkanoyloxymethyl esters, for example, pivaloyloxymethyl; phthalidyl esters; C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters, for example, 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters, for example, 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters, for example, 1-methoxycarbonyloxyethyl; and may be formed at any carboxyl group in the compounds of this invention. An *in vivo* hydrolysable (or cleavable) ester of a compound of formula (I) that contains a hydroxyl group includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxyl group(s). Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxyl include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and *N*-(dialkylaminoethyl)-*N*-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.

In an embodiment of the invention, the compound of formula (I) is selected from

1-[6-Chloro-5-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylacetyl)amino]-2-quinoliny]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-D-proline,

1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-
(3*R*)-3-piperidinecarboxylic acid,

5 6-Chloro-2-[4-(1,5-dihydro-5-oxo-4*H*-1,2,4-triazol-4-yl)-1-piperidinyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

4-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-1-
piperazineacetic acid,

6-Chloro-2-[(3*S*)-3-[[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-pyrrolidinyl]-*N*-
10 (tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-
4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-
4-piperidineacetic acid,

15 6-Chloro-2-[4-(2*H*-tetrazol-5-yl)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-
quinolinecarboxamide,

6-Chloro-2-[4-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)butyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

N-[(3*S*)-1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-
20 quinoliny]-3-pyrrolidinyl]-β-alanine,

N-[(3*S*)-1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-
quinoliny]-3-piperidinyl]-β-alanine,

6-Chloro-2-[(3*S*)-3-[[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-piperidinyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

25 6-Chloro-2-[(3*S*)-3-[methyl[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-pyrrolidinyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

4-[6-Chloro-5-[[[(2-tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl)amino]carbonyl]-2-quinoliny]-1-
piperazinepropanoic acid,

1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-4-
30 hydroxy-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-4-
phenyl-4-piperidinecarboxylic acid,

(1*R*,5*S*)-3-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinolinyl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid,

6-Chloro-2-[4-[[methylsulfonyl]amino]carbonyl]-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

6-Chloro-2-[4-[(hydroxyamino)carbonyl]-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

6-Chloro-2-[4-(1*H*-1,2,4-triazol-3-ylsulfonyl)-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

2-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinolinyl]-benzoic acid,

3-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinolinyl]-benzoic acid,

4-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinolinyl]-benzoic acid,

1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinolinyl]-4-methyl-4-piperidinecarboxylic acid,


N-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinolinyl]-β-alanine,

5-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinolinyl]-3-pyridinecarboxylic acid,


or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

The present invention further provides a process for the preparation of a compound of formula (I) as defined above or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, which comprises either:

(a) reacting a compound of formula (III)




wherein L^1 represents a leaving group (e.g. hydroxyl or halogen) and R^2 , R^3 , R^4 , p and q are as defined in formula (I), with a compound of formula (IV),



(IV)


wherein R^1 and n are as defined in formula (I); or

(b) reacting a compound of formula (V)



(V)


wherein R^2 , R^3 , R^4 , p and q are as defined in formula (I), with a compound of formula (VI)



(VI)


wherein L^2 represents a leaving group (e.g. hydroxyl or halogen) and R^1 and n are as defined in formula (I); or

(c) when R^3 represents a group Y^1R^6 or Z^1R^{10} wherein the atom directly attached to the quinoline group of formula (I) is a nitrogen atom, reacting a compound of formula (VII)




wherein L^3 is a leaving group (e.g. halogen, *para*-toluene sulphonate or methane
 5 sulphonate), and all other variables are as defined in relation to formula (I), with a
 compound of formula (VIII), $H-NY^{1''}R^{6''}$ or formula (IX), $H-NZ^{1''}R^{10''}$ wherein $NY^{1''}R^{6''}$
 or $NZ^{1''}R^{10''}$ make up a group of Y^1R^6 or Z^1R^{10} respectively as defined in formula (I); or

(d) when R^3 represents a group Y^1R^6 or Z^1R^{10} wherein the group directly attached to the
 10 quinoline group of formula (I) is CH_2CH_2 , reacting a compound of formula (VII) as
 defined in (c) above with a compound of formula (X), (XI), (XII) or (XIII)



wherein Y^1R^6 and $Z^1R^{10'}$ are suitably defined such that reaction of (VII) with (X), (XI),
 15 (XII) or (XIII) and subsequent hydrogenation of any resulting alkene or alkyne yields a
 compound wherein R^3 represents a group Y^1R^6 or Z^1R^{10} ; or

(e) when R^3 represents a group Y^1R^6 or Z^1R^{10} wherein the group directly attached to the
 quinoline group of formula (I) is CH_2CH_2N , reacting a compound of formula (VII) as
 20 defined in (c) above with a compound of formula (XIV)




wherein L^4 is a leaving group (eg. trialkyltin, dialkylboron or zinc), followed by reaction
 with a compound of formula (XV), $HNY^{1'''}R^{6'''}$ or (XVI) $HNZ^{1'''}R^{10'''}$, wherein $NY^{1'''}R^{6'''}$
 or $NZ^{1'''}R^{10'''}$ make up a group of Y^1R^6 or Z^1R^{10} respectively as defined in formula (I);

(f) when R^3 represents a group Y^1R^6 or Z^1R^{10} wherein the group directly attached to the quinoline group of formula (I) is CH_2N , reacting a compound of formula (VII) as defined in (c) above with a compound of formula (XIV) as defined in (e) above, followed by an oxidation reaction and then by reaction with a compound of formula (XV) or (XVI) as defined in (e) above under reductive amination conditions; or


(g) when R^3 represents a group Y^1R^6 or Z^1R^{10} wherein the group directly attached to the quinoline group of formula (I) is CH_2CH_2 , reacting a compound of formula (VII) as defined in (c) above with a compound of formula (XII) or (XIII) as defined above wherein Y^1R^6 , Z^1R^{10} are suitably defined such that saturation of the alkene and subsequent combination with a compound of formula (VII) yields a compound wherein R^3 represents a group Y^1R^6 or Z^1R^{10} ; or

(h) when R^8 or R^9 represent a tetrazole, reacting a compound of formula




wherein R^{6a} is 4- to 9- membered carbocyclic or heterocyclic ring and all other variables are as defined in relation to formula (I), with a compound of formula PN_3 wherein P is sodium, a trialkylsilyl, an alkyltin or ammonium; or

(i) when R^8 or R^9 represent a group of formula (XVII)




reacting a compound of formula (XXIII) or (XXIV) as defined above in (h) with hydroxylamine, followed by treatment with 1,1'-thiocarbonyldiimidazole and subsequent treatment with silica to yield a compound wherein R^8 or R^9 represent a group of formula (XVII) wherein J is S; alternatively reacting a compound of formula (XXVII) or (XXVIII) with hydroxylamine, followed by treatment with a chloroformate to yield a compound wherein R^8 or R^9 represent a group of formula (XVII) wherein J is O; or

(j) when R^8 or R^9 represent a group of formula (XVIII)




10 reacting a compound of formula



wherein R^{6a} is 4- to 9- membered carbocyclic or heterocyclic ring and all other variables are as defined in relation to formula (I), with phosgene or a phosgene equivalent followed by treatment with formyl hydrazine and subsequent treatment with base; or


(k) when R^8 or R^9 represent a group of formula (XIX)



reacting a compound of formula (XXV) or (XXVI) as defined above in (j) with ethyl chloroacetate, followed by reaction with (chlorosulfonyl)-carbamic acid, 1,1-dimethylethyl


ester and subsequent treatment with acid and base to yield a compound wherein R⁸ or R⁹ represent a group of formula (XIX); or

- (l) when R₃ represents a group Y¹R⁶ wherein Y¹ is a bond and R⁶ is an aromatic carbocyclic or heterocyclic ring substituted by carboxyl, reacting a compound of formula (VII) as defined in (c) above with a compound of formula (XXVII)



wherein M represents an organoboron group such as B(OH)₂, B(OⁱPr)₂, BEt₂ or a boronic acid pinacol cyclic ester and R^{6b} represents an aromatic carbocyclic or heterocyclic ring substituted by carboxyl or CO₂C₁₋₆alkyl, optionally followed by reaction with a base.

- (m) when R₃ represents a group Y¹R⁶ wherein Y¹ is a bond and R⁶ is an aromatic carbocyclic or heterocyclic ring substituted by carboxyl, reacting a compound of formula (VII) as defined in (c) above with a compound of formula (XXVIII)



wherein L⁴ represents a leaving group (e.g. halogen) and R^{6c} represents an aromatic carbocyclic or heterocyclic ring substituted by carboxyl, in the presence of a diboron compound such as 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane;

and optionally after (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) or (m) carrying out one or more of the following:

- converting the compound obtained to a further compound of the invention
- forming a pharmaceutically acceptable salt of the compound

- forming an *in vivo* hydrolysable ester of the compound.

In processes (a) and (b) the coupling reaction is conveniently carried out in an organic solvent such as dichloromethane, *N,N*-dimethylformamide or 1-methyl-2-pyrrolidinone.

5

If L¹ or L² represent a hydroxyl group, it may be necessary or desirable to use a coupling agent such as bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP). If L¹ or L² are chloride, such compounds may be conveniently prepared by treatment of the corresponding carboxylic acid derivative under standard conditions (such as thionyl chloride in dichloromethane with additional *N,N*-dimethylformamide) and used in a solvent such as acetone or dichloromethane with a suitable base such as potassium carbonate or triethylamine.

10

In process (c) the reaction may be performed in an organic solvent such as acetonitrile, *N,N*-dimethylformamide or 1-methyl-2-pyrrolidinone, and in the presence of a suitable base such as sodium hydride, triethylamine or potassium carbonate at a temperature in the range from, e.g. 50°C to 150°C, in particular from 80°C to 120°C, either in a microwave or conventional thermal conditions.

15

In process (d), the compound of formula (VII) may be conveniently reacted with a compound of formula (X), (XI), (XII) or (XIII) in an organic solvent such as acetonitrile, e.g. at ambient temperature (20°C), in the presence of catalytic bistrisphenylphosphine dichloride palladium(0), copper (I) iodide and a base (e.g. triethylamine). The subsequent hydrogenation reaction may use hydrogen gas with a catalyst such as 5% rhodium on carbon in a solvent, for example, ethyl acetate or ethanol, and at a pressure of 3 bar.

20

25

In process (e), the reaction with the vinyl compound of formula (XIV) may conveniently be carried out in a solvent such as *N,N*-dimethylformamide and in the presence of catalytic dichlorobis(triphenylphosphine)palladium, at elevated temperature, e.g. at about 70°C.

30

The subsequent addition reaction with the resultant compound may be performed under acidic or basic conditions, for example, in acetic acid in a solvent such as methanol or isopropanol at elevated temperature, e.g. at about 100°C.

In process (f), the reaction of the vinyl compound of formula (XIV) may be performed by procedures analogous to those outlined in the previous paragraph on process (e). The subsequent oxidation reaction may be carried out under standard conditions, for example, by using ozone followed by treatment with dimethylsulfide or triphenylphosphine in a suitable solvent such as dichloromethane, or, by using osmium tetroxide and sodium periodate in a suitable solvent such as 1,4-dioxane and water. The reductive amination step may be conveniently carried out in the presence of a reducing agent such as sodium cyanoborohydride, triacetoxyborohydride or sodium borohydride, in a polar solvent such as methanol, ethanol or dichloromethane either alone or in combination with acetic acid.

In process (g), the compound of formula (XII) or (XIII) is pre-treated by reaction with a hydroborating reagent (such as 9-borabicyclo[3.3.1]nonane or catecholborane) in a solvent (such as diethyl ether or tetrahydrofuran) at a temperature in the range from 0°C to 80°C (in particular from 60°C to 70°C) for about 2 to 3 hours, then cooling the reaction mixture to room temperature and adding a solution of a base (such as sodium hydroxide in water or *tri*-potassium orthophosphate in water) followed by a solution of the compound of formula (VII) in a solvent (such as *N,N*-dimethylformamide) and a palladium catalyst (such as *tetrakis*(triphenylphosphine)palladium(II)). The resulting reaction mixture is stirred at a temperature in the range from 25°C to 90°C (particularly from 60°C to 70°C) for about 2 to 24 hours to yield the desired compounds of formula (I).

In process (h), the compound of formula (XXIII) or (XXIV) is treated with a compound of the formula PN_3 in a solvent (such as toluene, *N,N*-dimethylformamide or 1-methyl-2-pyrrolidinone) optionally in the presence of catalyst (such as dibutyltin oxide) at a temperature in the range from 70°C to 120°C.

In process (i), when in the group of formula (XVII) $\text{J} = \text{O}$, a compound of formula (XXIII) or (XXIV) may be treated with hydroxylamine in a suitable solvent (such as methanol or ethanol) at a temperature in the range from 70°C to 130°C. The resulting intermediate is

treated with a suitable chloroformate (such as 2-ethylhexylchloroformate) in a suitable solvent (such as dichloromethane) and heated at a temperature in the range from 70°C to 150°C to give the desired compounds of the formula (I). Alternatively, when J = S, treatment of the hydroxylamine adduct with 1,1'-thiocarbonyldiimidazole in a suitable solvent (such as tetrahydrofuran) and addition of silica yields the desired compounds of the formula (I).

In process (j), the compound of formula (XXV) or (XXVI) is treated with phosgene or a phosgene equivalent (such as triphosgene or carbonyldiimidazole) in a suitable solvent (such as dichloromethane) with a suitable base (such as triethylamine). The resulting compound is further treated with formyl hydrazine and this subsequently with a base (such as potassium hydroxide) in a suitable solvent (such as methanol) at a temperature in the range from 50°C to 130°C to give the desired compounds of the formula (I).

In process (k), the compound of formula (XXV) or (XXVI) as defined above in (j) is treated with ethyl chloroacetate in a suitable solvent (such as acetonitrile) with a suitable base (such as triethylamine) at a temperature in the range from 50°C to 130°C. Treatment of this adduct with (chlorosulfonyl)-carbamic acid, 1,1-dimethylethyl ester in a suitable solvent (such as dichloromethane) and subsequent treatment with a suitable acid (such as trifluoroacetic acid) and a suitable base (such as sodium methoxide) to give the desired compounds of the formula (I).

In process (l), the coupling reaction is conveniently carried out in the presence of a catalyst such as tetrakis(triphenylphosphine)palladium(0), palladium(II) chloride, palladium(II) bromide, dichlorobis(triphenylphosphine)palladium(II), nickel(II) chloride, nickel(II) bromide or bis(triphenylphosphine)nickel(II) chloride, in the presence of a suitable solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene, toluene, xylene, methanol, ethanol or water. The reaction is preferably conducted in the presence of a suitable base such as sodium carbonate or potassium carbonate, pyridine, 4-dimethylaminopyridine, triethylamine or morpholine, and at a temperature in the range


10 to 250°C, preferably in the range 60 to 120°C, either in a microwave or under conventional thermal conditions. Where R^{6b} represents an aromatic carbocyclic or heterocyclic ring substituted CO₂C₁₋₆alkyl, the ester may be converted to carboxyl by reaction with a base such as sodium hydroxide in a solvent such as methanol or water, at a temperature in the range 0 to 100°C.

In process (m), the reaction is conveniently carried out in the presence of a catalyst such as tetrakis(triphenylphosphine)palladium(0), in the presence of a suitable solvent such as tetrahydrofuran or water. The reaction is preferably conducted in the presence of a suitable base such as sodium carbonate, and at a temperature in the range 10 to 250°C, preferably in the range 60 to 150°C, either in a microwave or conventional thermal conditions.

Compounds of formulae (III), (IV), (V), (VI), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XXIII), (XXIV), (XXV), (XXVI), (XXVII) and (XXVIII) are either commercially available, are known in the literature or may be prepared using known techniques.

Examples of preparation methods for certain of these compounds are given hereinafter in the examples. Other examples can be prepared by analogous methods. In particular, compounds of formula (VII) can be prepared by either


(i) reacting a compound of formula (XX)



wherein L¹ represents a leaving group (e.g. hydroxyl or halogen) and R², R⁴, p, q and L³ are as defined in formula (I), with a compound of formula (IV) as defined in (a) above;


(ii) reacting a compound of formula (XXI)

25



5 wherein R^2 , R^4 , L^3 , p and q are as defined in formula (I), with a compound of formula (VI) as defined in (b) above; or

(iii) reacting a compound of formula (XXII)



10

with a suitable amine of formula (IV) as defined above in (a), wherein L^5 is a halogen (e.g. bromine or iodine) and all other variables are as defined in relation to formula (I) with a suitable source of carbon monoxide and a suitable catalyst.

15 In (i) and (ii) the coupling reaction is conveniently carried out in an organic solvent such as dichloromethane, *N,N*-dimethylformamide or 1-methyl-2-pyrrolidinone and reaction conditions analogous to those described above in relation to steps (a) and (b) may be employed;

20 In (iii) suitable catalysts include palladium catalysts such as dichlorobis(triphenylphosphine)palladium(II) and the reaction may be carried out in an inert solvent such as *N*-methyl pyrrolidinone, at a temperature between 25°C and 150°C, preferably 100°C and under a 1-15 bar pressure of carbon monoxide, preferably 6 bar to give the desired compounds of the formula (VII).

25

Compounds of formula (XX), (XXI) and (XXII) are either commercially available, are known in the literature or may be prepared using known techniques.

Compounds of formula (XXI) may be prepared by nitration of the corresponding 2-chloroquinoline under standard conditions (such as nitric acid and sulfuric acid at a temperature in the range of 0°C to 100°C) followed by subsequent reduction to the corresponding aniline derivative under standard conditions (such as iron powder, acetic acid, hydrochloric acid, water and ethanol at a temperature in the range of 20°C to 100°C). Alternatively, a suitable nitro derivative with no substitution at the 2-position may be functionalised to compounds of formula (XXI) by N-oxidation of the quinoline nitrogen under standard conditions (such as peracetic acid in acetic acid at a temperature in the range of 0°C to 60°C) and further conversion to its 2-chloro derivative by treatment with a suitable chlorinating agent (such as phosphorus oxychloride at a temperature in the range of 0°C to 100°C). 2-Hydroxy compounds may be similarly converted to the 2-chloro derivatives by treatment with similar chlorinating agents.

Compounds of formula (XX) wherein L¹ is OH may be prepared from an appropriately substituted 5-bromo-2-halo-quinoline, such as 5-bromo-2,6-dichloroquinoline, by treatment with a Grignard reagent followed carbon dioxide. Suitable Grignard reagents include isopropylmagnesium chloride and the reaction may be carried out in an inert solvent such as tetrahydrofuran or diethyl ether, at a temperature from -30°C to 30°C, but preferentially at 0°C. The reaction may be poured onto solid carbon dioxide or more preferably CO₂ gas may be bubbled through the reaction mixture.

The appropriately substituted 5-bromo-2-halo-quinoline may be prepared by bromination of an appropriately substituted 2-haloquinoline such as 2,6-dichloroquinoline. The reaction may be carried by treatment with bromine in the presence of a Lewis acid such as aluminium trichloride at temperatures between -10°C to 150°C, preferably at 120°C, in the absence of solvent.

The appropriately substituted 5-bromo-quinolines may be prepared by literature methods (J Heterocyclic Chem., 1967, 4, 410, Khimiya Geterotsiklicheskikh Soedinenii, 1988, 8, 1084).

- 5 Compounds of formula (I) can be converted into further compounds of formula (I) using standard procedures. For example, compounds of formula (I) in which R^2 represents a halogen atom may be converted to a corresponding compound of formula (I) in which R^2 represents a C_1 - C_6 alkyl group by reaction with an alkyl Grignard reagent (e.g. methyl magnesium bromide) in the presence of a catalyst such as [1,3-
10 *bis*(diphenylphosphino)propane]dichloronickel(II) in a solvent such as tetrahydrofuran.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus,
15 the preparation of the compounds of formula (I) may involve, at various stages, the addition and removal of one or more protecting groups.

The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective
20 Groups in Organic Synthesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1999).

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt thereof, such as an acid addition salt, e.g. a hydrochloride, hydrobromide, phosphate,
25 fumarate, maleate, citrate or methanesulphonate, or an alkali metal salt e.g. a sodium or potassium salt, using conventional methods. Other pharmaceutically acceptable salts, as well as *in vivo* hydrolysable esters, may also be prepared by known methods.

A compound of the invention, or a pharmaceutically acceptable salt or an *in vivo*
30 hydrolysable ester thereof, can be used in the treatment of:

1. respiratory tract: obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin

and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases;

5 hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of
10 chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus;

15 2. bone and joints: arthritides associated with or including osteoarthritis/osteoarthrosis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and low back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy; septic arthritis and other infection-
20 related arthropathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed
25 connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositis and polymyositis; polymyalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis
30 nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; low back pain; Familial

Mediterranean fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; drug-induced arthralgias, tendonitides, and myopathies;

3. pain and connective tissue remodelling of musculoskeletal disorders due to injury [for example sports injury] or disease: arthritides (for example rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy), other joint disease (such as intervertebral disc degeneration or temporomandibular joint degeneration), bone remodelling disease (such as osteoporosis, Paget's disease or osteonecrosis), polychondritits, scleroderma, mixed connective tissue disorder, spondyloarthropathies or periodontal disease (such as periodontitis);

4. skin: psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions;

5. eyes: blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune; degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral, fungal, and bacterial;

6. gastrointestinal tract: glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; coeliac disease, irritable bowel syndrome, and food-related allergies which may have effects remote from the gut (for example migraine, rhinitis or eczema);

7. abdominal: hepatitis, including autoimmune, alcoholic and viral; fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic;

8. genitourinary: nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer;

acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvo-vaginitis; Peyronie's disease; erectile dysfunction (both male and female);

9. allograft rejection: acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or
5 chronic graft versus host disease;

10. CNS: Alzheimer's disease and other dementing disorders including CJD and nvCJD; amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; acute and chronic pain (acute, intermittent or persistent, whether of central or peripheral origin) including visceral
10 pain, headache, migraine, trigeminal neuralgia, atypical facial pain, joint and bone pain, pain arising from cancer and tumor invasion, neuropathic pain syndromes including diabetic, post-herpetic, and HIV-associated neuropathies; neurosarcoidosis; central and peripheral nervous system complications of malignant, infectious or autoimmune processes;

11. other auto-immune and allergic disorders including Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-IgE syndrome, antiphospholipid syndrome;

12. other disorders with an inflammatory or immunological component; including acquired immune deficiency syndrome (AIDS), leprosy, Sezary syndrome, and
20 paraneoplastic syndromes;

13. cardiovascular: atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis, inflammatory and auto-immune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; disorders of the proximal and
25 peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins;

14. oncology: treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as
30 Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,

15. gastrointestinal tract: Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, microscopic colitis, indeterminant colitis, irritable bowel disorder, irritable bowel syndrome, non-inflammatory diarrhea, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and
5 eczema.

Accordingly, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as hereinbefore defined for use in therapy.

10 In another aspect, the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

15 In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

20 The invention further provides a method of effecting immunosuppression (e.g. in the treatment of rheumatoid arthritis, osteoarthritis, irritable bowel disease, atherosclerosis or psoriasis) which comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as hereinbefore defined to a patient.

25 The invention also provides a method of treating an obstructive airways disease (e.g. asthma or COPD) which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as hereinbefore defined to a patient.

30 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the

disorder indicated. The daily dosage of the compound of formula (I)/salt ("active ingredient") may be in the range from 0.001 mg/kg to 30 mg/kg.

The compounds of formula (I) and pharmaceutically acceptable salts or *in vivo* hydrolysable esters thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt ("active ingredient") is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically acceptable adjuvant, diluent or carrier, all percentages by weight being based on total composition.

Thus, the present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical composition of the invention may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.

The invention further relates to combination therapies wherein a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.

In particular, for the treatment of the inflammatory diseases such as (but not restricted to) rheumatoid arthritis, osteoarthritis, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), psoriasis, and inflammatory bowel disease, the compounds of the invention may be combined with agents listed below.

5

Non-steroidal anti-inflammatory agents (hereinafter NSAIDs) including non-selective cyclo-oxygenase COX-1 / COX-2 inhibitors whether applied topically or systemically (such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin); selective
10 COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumarocoxib, parecoxib and etoricoxib); cyclo-oxygenase inhibiting nitric oxide donors (CINODs); glucocorticosteroids (whether administered by topical, oral, intramuscular, intravenous, or intra-articular routes); methotrexate; leflunomide; hydroxychloroquine; d-penicillamine;
15 auranofin or other parenteral or oral gold preparations; analgesics; diacerein; intra-articular therapies such as hyaluronic acid derivatives; and nutritional supplements such as glucosamine.

The present invention still further relates to the combination of a compound of the
20 invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, together with a cytokine or agonist or antagonist of cytokine function, (including agents which act on cytokine signalling pathways such as modulators of the SOCS system) including alpha-, beta-, and gamma-interferons; insulin-like growth factor type I (IGF-1); interleukins (IL) including IL1 to 17, and interleukin antagonists or inhibitors such as
25 anakinra; tumour necrosis factor alpha (TNF- α) inhibitors such as anti-TNF monoclonal antibodies (for example infliximab; adalimumab, and CDP-870) and TNF receptor antagonists including immunoglobulin molecules (such as etanercept) and low-molecular-weight agents such as pentoxifylline.

In addition the invention relates to a combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, with a monoclonal antibody targeting B-Lymphocytes (such as CD20 (rituximab), MRA-aIL16R and T-Lymphocytes, CTLA4-Ig, HuMax Il-15).

5

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, with a modulator of chemokine receptor function such as an antagonist of CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family.

10

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, with an inhibitor of matrix metalloprotease (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-9 and MMP-12, including agents such as doxycycline.

15

20

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; a N-(5-substituted)-thiophene-2-alkylsulfonamide; 2,6-di-tert-butylphenolhydrazones; a methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; or an indole or quinoline compound such as MK-591, MK-886, and BAY x 1005.

25

30

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and a receptor antagonist for leukotrienes (LT) B₄, LTC₄, LTD₄, and LTE₄ selected from the group consisting of the phenothiazin-3-1s such as L-651,392; amidino compounds such as CGS-
5 25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

The present invention still further relates to the combination of a compound of the
10 invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and a phosphodiesterase (PDE) inhibitor such as a methylxanthanine including theophylline and aminophylline; a selective PDE isoenzyme inhibitor including a PDE₄ inhibitor an inhibitor of the isoform PDE_{4D}, or an inhibitor of PDE₅.

15 The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine; applied orally, topically or parenterally.

20 The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and a proton pump inhibitor (such as omeprazole) or a gastroprotective histamine type 2 receptor antagonist.

25 The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and an antagonist of the histamine type 4 receptor.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and an alpha-1/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride or ethylnorepinephrine hydrochloride.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and an anticholinergic agents including muscarinic receptor (M1, M2, and M3) antagonist such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and a beta-adrenoceptor agonist (including beta receptor subtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, or pirbuterol, or a chiral enantiomer thereof.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and a chromone, such as sodium cromoglycate or nedocromil sodium.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, with a glucocorticoid, such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, with an agent that modulates a nuclear hormone receptor such as PPARs.

5 The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, together with an immunoglobulin (Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (for example omalizumab).

10 The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and another systemic or topically-applied anti-inflammatory agent, such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.

15 The invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and combinations of aminosalicylates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine; and immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.

20

The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, together with an antibacterial agent such as a penicillin derivative, a tetracycline, a macrolide, a beta-lactam, a fluoroquinolone, metronidazole, an inhaled aminoglycoside; an antiviral agent
25 including acyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir, amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; a protease inhibitor such as indinavir, nelfinavir, ritonavir, and saquinavir; a nucleoside reverse transcriptase inhibitor such as didanosine, lamivudine, stavudine, zalcitabine or zidovudine; or a non-nucleoside reverse transcriptase inhibitor such as nevirapine or efavirenz.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and a cardiovascular agent such as a calcium channel blocker, a beta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist; a
5 lipid lowering agent such as a statin or a fibrate; a modulator of blood cell morphology such as pentoxifylline; thrombolytic, or an anticoagulant such as a platelet aggregation inhibitor.

The present invention further relates to the combination of a compound of the invention, or
10 a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, and a CNS agent such as an antidepressant (such as sertraline), an anti-Parkinsonian drug (such as deprenyl, L-dopa, ropinirole, pramipexole, a MAOB inhibitor such as selegine and rasagiline, a COMT inhibitor such as tasmar, an A-2 inhibitor, a dopamine reuptake inhibitor, an NMDA antagonist, a nicotine agonist, a dopamine agonist or an inhibitor of
15 neuronal nitric oxide synthase), or an anti-Alzheimer's drug such as donepezil, rivastigmine, tacrine, a COX-2 inhibitor, propentofylline or metrifonate.

The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof,
20 and an agent for the treatment of acute or chronic pain, such as a centrally or peripherally-acting analgesic (for example an opioid or derivative thereof), carbamazepine, phenytoin, sodium valproate, amitriptyline or other anti-depressant agent-s, paracetamol, or a non-steroidal anti-inflammatory agent.

25 The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, together with a parenterally or topically-applied (including inhaled) local anaesthetic agent such as lignocaine or a derivative thereof.

A compound of the present invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, can also be used in combination with an anti-osteoporosis agent including a hormonal agent such as raloxifene, or a biphosphonate such as alendronate.

5 The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, together with a: (i) tryptase inhibitor; (ii) platelet activating factor (PAF) antagonist; (iii) interleukin converting enzyme (ICE) inhibitor; (iv) IMPDH inhibitor; (v) adhesion molecule inhibitors including VLA-4 antagonist; (vi) cathepsin; (vii) kinase inhibitor such as an inhibitor of tyrosine kinase (such as Btk, Itk, Jak3 or MAP, for example Gefitinib or Imatinib mesylate), a serine / threonine kinase (such as an inhibitor of a MAP kinase such as p38, JNK, protein kinase A, B or C, or IKK), or a kinase involved in cell cycle regulation (such as a cyclin dependent kinase); (viii) glucose-6 phosphate dehydrogenase inhibitor; (ix) kinin-B1. - or B2. -receptor antagonist; (x) anti-gout agent, for example colchicine; (xi) xanthine oxidase inhibitor, for example allopurinol; (xii) uricosuric agent, for example probenecid, sulfinpyrazone or benzbromarone; (xiii) growth hormone secretagogue; (xiv) transforming growth factor (TGF β); (xv) platelet-derived growth factor (PDGF); (xvi) fibroblast growth factor for example basic fibroblast growth factor (bFGF); (xvii) granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) capsaicin cream; (xix) tachykinin NK1 or NK3 receptor antagonist such as NKP-608C, SB-233412 (talnetant) or D-4418; (xx) elastase inhibitor such as UT-77 or ZD-0892; (xxi) TNF-alpha converting enzyme inhibitor (TACE); (xxii) induced nitric oxide synthase (iNOS) inhibitor; (xxiii) chemoattractant receptor-homologous molecule expressed on TH2 cells, (such as a CRTH2 antagonist); (xxiv) inhibitor of P38; (xxv) agent modulating the function of Toll-like receptors (TLR), (xxvi) agent modulating the activity of purinergic receptors such as P2X7; or (xxvii) inhibitor of transcription factor activation such as NFkB, API, or STATS.

A compound of the invention, or a pharmaceutically acceptable salt thereof, can also be used in combination with an existing therapeutic agent for the treatment of cancer, for example suitable agents include:

- (i) an antiproliferative/antineoplastic drug or a combination thereof, as used in medical oncology, such as an alkylating agent (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan or a nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like 5-fluorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin or mithramycin); an antimitotic agent (for example a vinca alkaloid such as vincristine, vinblastine, vindesine or vinorelbine, or a taxoid such as taxol or taxotere); or a topoisomerase inhibitor (for example an epipodophyllotoxin such as etoposide, teniposide, amsacrine, topotecan or a camptothecin);
- (ii) a cytostatic agent such as an antioestrogen (for example tamoxifen, toremifene, raloxifene, droloxifene or idoxifyfene), an oestrogen receptor down regulator (for example fulvestrant), an antiandrogen (for example bicalutamide, flutamide, nilutamide or cyproterone acetate), a LHRH antagonist or LHRH agonist (for example goserelin, leuprorelin or buserelin), a progestogen (for example megestrol acetate), an aromatase inhibitor (for example as anastrozole, letrozole, vorazole or exemestane) or an inhibitor of 5 α -reductase such as finasteride;
- (iii) an agent which inhibits cancer cell invasion (for example a metalloproteinase inhibitor like marimastat or an inhibitor of urokinase plasminogen activator receptor function);
- (iv) an inhibitor of growth factor function, for example: a growth factor antibody (for example the anti-erbb2 antibody trastuzumab, or the anti-erbb1 antibody cetuximab [C225]), a farnesyl transferase inhibitor, a tyrosine kinase inhibitor or a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family (for example an EGFR family tyrosine kinase inhibitor such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) or 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), an

inhibitor of the platelet-derived growth factor family, or an inhibitor of the hepatocyte growth factor family;

(v) an antiangiogenic agent such as one which inhibits the effects of vascular endothelial growth factor (for example the anti-vascular endothelial cell growth factor antibody

5 bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354), or a compound that works by another mechanism (for example linomide, an inhibitor of integrin $\alpha v \beta 3$ function or an angiostatin);

(vi) a vascular damaging agent such as combretastatin A4, or a compound disclosed in WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 or WO 02/08213;

10 (vii) an agent used in antisense therapy, for example one directed to one of the targets listed above, such as ISIS 2503, an anti-ras antisense;

(viii) an agent used in a gene therapy approach, for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or

15 a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; or


(ix) an agent used in an immunotherapeutic approach, for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony

20 stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

The present invention will now be further explained by reference to the following

25 illustrative examples. In the examples the NMR spectra were measured on a Varian Unity spectrometer at a proton frequency of either 300 or 400 MHz. The MS spectra were measured on either an Agilent 1100 MSD G1946D spectrometer or a Hewlett Packard HP1100 MSD G1946A spectrometer. Preparative HPLC separations were performed using a Waters Symmetry[®] or Xterra[®] column using 0.1% aqueous trifluoroacetic acid:

30 acetonitrile, 0.1% aqueous ammonia: acetonitrile or 0.1% ammonium acetate: acetonitrile as the eluent. SCX and NH₂ resin were obtained from Varian Incorporated.

Example 1**1-[6-Chloro-5-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylacetyl)amino]-2-quinolinyl]-4-piperidinecarboxylic acid****a) 1-[6-Chloro-5-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylacetyl)amino]-2-quinolinyl]-4-piperidinecarboxylic acid, ethyl ester**

To *N*-(2,6-dichloro-5-quinolinyl)-tricyclo[3.3.1.1^{3,7}]decane-1-acetamide (prepared as described in WO2003080579) (150 mg) and triethylamine (500 μ L) in acetonitrile (2 mL) was added 4-piperidinecarboxylic acid, ethyl ester (500 μ L). The mixture was heated in a microwave for 40 minutes at 120°C and then cooled to room temperature. The resulting precipitate was removed by filtration and purified by chromatography (SiO₂, methanol:dichloromethane 5:95 as eluant) to afford the subtitled compound as a solid (100 mg).

MS: APCI(+ve) 510.3/512.3 (M+H⁺).

b) 1-[6-Chloro-5-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylacetyl)amino]-2-quinolinyl]-4-piperidinecarboxylic acid

Potassium hydroxide (100 mg) was added to a solution of 1-[6-chloro-5-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylacetyl)amino]-2-quinolinyl]-4-piperidinecarboxylic acid, ethyl ester (Example 1(a)) in methanol (2 mL) and water (1 mL). The mixture was stirred at 80°C for 30 minutes. The reaction mixture was acidified to pH5 with aqueous 2M hydrochloric acid. The resulting precipitate was removed by filtration and purified by chromatography (SiO₂, methanol:dichloromethane:acetic acid 5:95:1 as eluant). Further


purification by HPLC (Symmetry - 0.1% aqueous ammonium acetate / acetonitrile) afforded the title product (25 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 9.70 (1H, s), 7.88 (1H, d), 7.63-7.42 (2H, m), 7.32 (1H, d), 4.48-4.32 (2H, m), 3.18-2.97 (2H, m), 2.20 (2H, s), 2.05-1.81 (8H, m), 1.79-1.45 (12H, m). MS: APCI(-ve) 480.2/482.2 (M-H⁺).

m.p. 240-241°C

Example 2

10 **1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-D-proline**



To 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (250 mg) and triethylamine (269 μL) in acetonitrile (4 mL) was added D-proline 1,1-dimethylethyl ester (330 mg). The mixture was heated in a microwave for 90 minutes at 140°C and then cooled to room temperature. The solvent was removed from the reaction followed by the addition of water and acetic acid (1 mL) which was subsequently extracted three times with dichloromethane. The combined organics were washed once with water, once with brine followed by the addition of trifluoroacetic acid (1 mL) and stirred for 12 h. The solvent was removed followed by the addition of methanol and placed down a Varian NH₂ cartridge, washed with methanol and eluted using 10% acetic acid in methanol. Removal of solvent afforded the title compound (265 mg).

¹H NMR (300 MHz, d₆-DMSO) δ 8.54 (1H, t), 7.79 (1H, d), 7.54 - 7.45 (2H, m), 7.00 (1H, s), 4.62 - 4.55 (1H, m), 3.72 - 3.54 (2H, m), 3.04 (2H, d), 2.35 - 2.22 (1H, m), 2.12 - 1.92 (6H, m), 1.73 - 1.53 (12H, m).


MS: APCI(+ve) 468 (M+H⁺).

5 m.p. 157-160°C

Example 3

1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-
(3*R*)-3-piperidinecarboxylic acid

10



To 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (250 mg) and triethylamine (536 μL) in acetonitrile (4 mL) was added (3*R*)-3-piperidinecarboxylic acid ethyl ester L-tartrate (591 mg). The mixture was heated in a microwave for 40 minutes at 140°C and then cooled to room temperature. Sodium hydroxide solution (2M, 2 mL) and methanol (2 mL) were added to the reaction and heated in a microwave at 70°C for 30 minutes. The reaction was acidified with hydrochloric acid followed by removal of volatiles, dissolved in dimethylsulphoxide / methanol and purified as described in Example 2. Removal of solvent afforded the title compound (73 mg).

20


¹H NMR (400 MHz, d₆-DMSO) δ 8.54 (1H, t), 7.77 (1H, d), 7.53 (2H, dd), 7.37 (1H, d), 4.55 - 4.48 (1H, m), 4.27 - 4.20 (1H, m), 3.22 - 3.11 (2H, m), 3.03 (2H, d), 2.46 - 2.35 (1H, m), 2.02 - 1.93 (4H, m), 1.76 - 1.54 (14H, m), 1.53 - 1.39 (1H, m).

25 MS: APCI(-ve) 480 (M-H⁺).

m.p. 257-262°C

Example 4

6-Chloro-2-[4-(1,5-dihydro-5-oxo-4*H*-1,2,4-triazol-4-yl)-1-piperidiny]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide



To 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (250 mg), *tert*-butylammonium bromide (206 mg) and triethylamine (178 μ L) in acetonitrile (4 mL) was added 2,4-dihydro-4-(4-piperidiny)-3*H*-1,2,4-triazol-3-one (prepared as described in WO2003080579) (216 mg). The mixture was heated in a microwave for 2.5 h at 140°C and then cooled to room temperature. The resulting precipitate was collected by filtration, triturated with refluxing methanol, cooled and filtered. The resulting product was taken up in dimethylsulfoxide and absorbed onto SCX, washed with methanol and eluted with 10% ammonia in methanol. The solution was left for 12 h before the precipitate was filtered to afford the title compound (79 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 11.64 (1H, s), 8.55 (1H, t), 7.98 - 7.96 (1H, m), 7.80 (1H, d), 7.55 (2H, dd), 7.43 (1H, d), 4.71 (2H, d), 4.12 - 4.02 (1H, m), 3.10 - 3.00 (4H, m), 1.99 - 1.89 (5H, m), 1.84 - 1.72 (2H, m), 1.72 - 1.54 (12H, m)

MS: APCI(+ve) 521 (M+H⁺).

m.p. 294-295°C

Example 5

4-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-1-piperazineacetic acid



To 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared
 5 as described in WO2003080579) (250 mg) and triethylamine (179 μ L) in acetonitrile (3
 mL) was added 1-piperazineacetic acid ethyl ester (332 mg). The mixture was heated in a
 microwave for 60 minutes at 120°C and then cooled to room temperature. The reaction
 was added to 1M sodium hydroxide solution which was then extracted three times with
 dichloromethane. The combined organics were washed with water,
 10 brine and dried. The crude mixture was redissolved in methanol (2 mL) and aqueous
 sodium hydroxide (2M, 2 mL) added. The mixture was heated in a microwave for 20
 minutes at 70°C after which the reaction was acidified with hydrochloric acid and volatiles
 removed. The product was triturated with water, filtered and redissolved in methanol.
 Purification (Varian NH₂ cartridge, eluted with methanol and then 10% acetic acid in
 15 methanol) afforded the title compound (78 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 8.55 (1H, t), 7.79 (1H, d), 7.55 (2H, dd), 7.36 (1H, d),
 3.76 - 3.69 (4H, m), 3.19 (2H, s), 3.04 (2H, d), 2.70 - 2.61 (4H, m), 1.96 (3H, s), 1.73 -
 1.65 (3H, m), 1.65 - 1.53 (9H, m).

MS: APCI(+ve) 497 (M+H⁺).

m.p. 179-183°C

Example 6

6-Chloro-2-[(3*S*)-3-[[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-pyrrolidinyl]-*N*-
 25 (tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide



a) 3-[(3S)-3-Pyrrolidinylamino]-propanenitrile

3-[[[(3S)-1-(Phenylmethyl)-3-pyrrolidinyl]amino]-propanenitrile (WO2000075137) (0.6 g), 20% palladium hydroxide on carbon (0.15 g), 1,4-cyclohexadiene (3 mL) and ethanol (2 mL) were loaded into a vial and heated at 100°C for 90 minutes within a microwave. The reaction mixture was filtered and volatiles removed under vacuum to afford the sub-title compound (0.304 g).

MS: APCI(+ve) 140.3 (M+H⁺).

b) 6-Chloro-2-[(3S)-3-[(2-cyanoethyl)amino]-1-pyrrolidinyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

To 2,6-dichloro-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (250 mg) and triethylamine (267 µL) in acetonitrile (3 mL) was added 3-[(3S)-3-pyrrolidinylamino]-propanenitrile (Example 6 (a)) (267 mg). The mixture was heated in a microwave for 3 h at 130°C and then cooled to room temperature. Purification by HPLC (Symmetry - 0.1% aqueous ammonium acetate / acetonitrile) afforded the sub-title compound (200 mg).

MS: APCI(+ve) 492 (M+H⁺).

c) 6-Chloro-2-[(3*S*)-3-[[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-pyrrolidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

To 6-chloro-2-[(3*S*)-3-[(2-cyanoethyl)amino]-1-pyrrolidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (Example 6 (b)) (200 mg), was added

trimethylsilylazide (162 μ L), dibutyltin oxide (10 mg) and toluene (4 mL). The mixture was heated in a microwave for 90 minutes at 110°C and then cooled to room temperature.

Methanol (5 mL) was added to the crude mixture which was then absorbed onto a Varian NH₂ cartridge, washed with methanol and eluted with 10% acetic acid in methanol. The solvent was removed and the solid triturated with acetonitrile to afford the title compound (76 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 8.56 (1H, t), 7.78 (1H, d), 7.54 (2H, dd), 7.01 (1H, d), 3.83 - 3.76 (1H, m), 3.72 - 3.63 (2H, m), 3.59 - 3.47 (2H, m), 3.14 - 3.08 (2H, m), 3.06 - 2.98 (4H, m), 2.29 - 2.19 (1H, m), 2.05 - 1.94 (1H, m), 1.96 (3H, s), 1.72 - 1.65 (3H, m), 1.64 - 1.54 (9H, m).

MS: APCI(+ve) 535 (M+H⁺).

m.p. 174-177°C

Example 7

1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid




The title compound was prepared as described in Example 5 using 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in

WO2003080579) (250 mg), triethylamine (179 μ L) and 4-piperidinecarboxylic acid ethyl ester (303 mg) in acetonitrile (4 mL) to afford the title compound (33 mg).

^1H NMR (400 MHz, d_6 -DMSO) δ 8.53 (1H, t), 7.76 (1H, d), 7.52 (2H, dd), 7.35 (1H, d), 4.37 (2H, d), 3.13 - 3.01 (4H, m), 1.96 (3H, s), 1.90 - 1.80 (5H, m), 1.75 - 1.45 (12H, m).
MS: APCI(+ve) 482 ($\text{M}+\text{H}^+$).
m.p. 231-235°C

Example 8


1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]]-4-piperidineacetic acid



The title compound was prepared as described in Example 5 using 2,6-dichloro-*N*-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (250 mg), triethylamine (179 μ L) and 4-piperidineacetic acid ethyl ester (329 mg) in acetonitrile (4 mL). Further purification was achieved by trituration with hot acetonitrile which was filtered to afford the title compound (29 mg).

^1H NMR (400 MHz, d_6 -DMSO) δ 8.53 (1H, t), 7.76 (1H, d), 7.52 (2H, dd), 7.35 (1H, d), 4.52 (2H, d), 3.03 (2H, d), 2.94 (2H, t), 2.17 (2H, d), 2.04-1.92 (4H, m), 1.77 (2H, d), 1.72-1.53 (12H, m), 1.25-1.10 (2H, m).
MS: APCI(+ve) 496($\text{M}+\text{H}^+$).

m.p. 212-214°C

Example 9**6-Chloro-2-[4-(2*H*-tetrazol-5-yl)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide**

a) 6-Chloro-2-(4-cyanobutyl)-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

2,6-Dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (500 mg), *tetrakis*(triphenylphosphine)palladium (74 mg) and 0.5M cyanobutylzinc bromide in tetrahydrofuran (20 mL) were refluxed under nitrogen for 1 hour. The reaction was cooled to room temperature before the addition of saturated ammonium chloride solution which was subsequently extracted three times with ethyl acetate. The combined organics were washed with water, brine and dried to afford the sub-title compound (652 mg).

MS: APCI(+ve) 436 (M+H⁺).

b) 6-Chloro-2-[4-(2*H*-tetrazol-5-yl)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

The title compound was prepared as described in Example 6 (c) using 6-chloro-2-(4-cyanobutyl)-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (Example 9 (a)) (200 mg), trimethylsilylazide (183 μ L), dibutyltin oxide (15 mg) and toluene (2 mL).

Further purification was achieved by recrystallisation from methanol / acetonitrile to afford the title compound (90 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 8.62 (1H, t), 8.02 (1H, d), 7.96 (1H, d), 7.76 (1H, d),
5 7.56 (1H, d), 3.07 (2H, d), 2.95 (4H, quintet), 1.96 (3H, s), 1.85 - 1.73 (4H, m), 1.72 - 1.54
(12H, m).

MS: APCI(+ve) 479 (M+H⁺).

m.p. 221°C

10 Example 10

6-Chloro-2-[4-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide



a) 2-[5-Amino-5-(hydroxyimino)pentyl]-6-chloro-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

To 6-chloro-2-(4-cyanobutyl)-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (Example 9 (a)) (250 mg) in ethanol (2 mL) was added hydroxylamine (50%w/v solution) (300 μL). The mixture was heated in a microwave for 50 minutes at 90°C and then cooled to room temperature before removal of volatiles to
20 afford the sub-title compound (280 mg).

MS: APC(+ve) 469 (M+H⁺).

b) 6-Chloro-2-[4-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)butyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

To a stirred solution of 2-[5-amino-5-(hydroxyimino)pentyl]-6-chloro-N-

(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (Example 10 (a)) (180 mg)

and pyridine (34 μ L) in dichloromethane (5 mL) cooled to 0°C was added 2-ethylhexyl-chloroformate (75 μ L). After 10 minutes the ice bath was removed and stirred for 2 h

before volatiles were removed under reduced pressure. The resulting residue was added to *iso*-hexane and heated in a microwave for 20 minutes at 140°C. The reaction was cooled to

room temperature followed by the addition of methanol (5 mL). The resulting solution was

absorbed on a Varian NH₂ cartridge, washed with methanol and eluted using 10% acetic acid in methanol. Further purification (SiO₂, methanol:dichloromethane 2:98 as eluant)


afforded the title compound (18 mg).

¹H NMR (300 MHz, d₆-DMSO) δ 12.15 (1H, s), 8.62 (1H, t), 8.03 (1H, d), 7.97 (1H, d), 7.76 (1H, d), 7.57 (1H, d), 3.07 (2H, d), 2.95 (2H, t), 2.59 - 2.51 (2H, m), 1.97 (3H, s), 1.88 - 1.75 (2H, m), 1.73 - 1.55 (14H, m).

MS: APCI(+ve) 495 (M+H⁺).

Example 11

N-[(3*S*)-1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinolinyl]-3-pyrrolidinyl]- β -alanine




To 6-chloro-2-[(3*S*)-3-[(2-cyanoethyl)amino]-1-pyrrolidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (Example 6 (b)) (150 mg) was added potassium hydroxide (68 mg), water (500 μ L) and methanol (3 mL). The mixture was heated in a microwave for 3 h at 90°C before being cooled to room temperature. The reaction was treated with ammonia and volatiles removed under reduced pressure. Purification (SiO₂, methanol:dichloromethane:ammonia 5:94:1 increasing to 10:90:1 as eluant) gave the solid which was further purified using a Varian NH₂ cartridge, washed with methanol and eluted using 10% acetic acid in methanol. The solvent was removed to afford the title compound (71 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.55 (1H, t), 7.76 (1H, d), 7.54 (1H, d), 7.49 (1H, d), 6.98 (1H, d), 3.75 - 3.68 (1H, m), 3.67 - 3.58 (1H, m), 3.57 - 3.47 (1H, m), 3.47 - 3.40 (1H, m), 3.39 - 3.31 (1H, m), 3.03 (2H, d), 2.84 - 2.76 (2H, m), 2.30 (2H, t), 2.19 - 2.09 (1H, m), 1.96 (3H, s), 1.88 - 1.81 (1H, m), 1.72 - 1.65 (3H, m), 1.65 - 1.54 (9H, m).

MS: APCI(+ve) 511 (M+H⁺).

Example 12

N-[(3*S*)-1-[6-Chloro-5-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-3-piperidiny]- β -alanine



a) 2-[(3*S*)-3-Amino-1-piperidinyl]-6-chloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

To 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (389 mg) in triethylamine (4 mL) was added (3*S*)-3-piperidinamine (200 mg). The mixture was heated in a microwave for 60 minutes at 140°C and then cooled to room temperature before being poured onto water followed by the

addition of sodium hydrogen carbonate solution. This solution was extracted with dichloromethane and the combined organics washed with water and brine. Removal of the solvent afforded the sub-title compound (450 mg).

5 MS: APCI(+ve) 453 ($M+H^+$).

b) 6-Chloro-2-[(3*S*)-3-[(2-cyanoethyl)amino]-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

2-[(3*S*)-3-Amino-1-piperidinyl]-6-chloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (Example 12 (a)) (200 mg) in 2-propenenitrile (1 mL) was heated in a microwave for 40 minutes at 120°C and then cooled to room temperature before volatiles were removed under reduced pressure. The residue was dissolved in methanol and absorbed onto SCX, washed with methanol and eluted with 10% ammonia in methanol. The solvent was removed to afford the sub-title compound (160 mg).

15

MS: APCI(+ve) 506 ($M+H^+$).

c) *N*-[(3*S*)-1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinolinyl]-3-piperidinyl]-β-alanine

20 To 6-chloro-2-[(3*S*)-3-[(2-cyanoethyl)amino]-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (Example 12 (b)) (130 mg) in methanol (5 mL) was added sodium hydroxide solution (47%w/v) (200 μL). The mixture was heated in a microwave for 120 minutes at 90°C and then cooled to room temperature before volatiles were removed under reduced pressure. The residue was acidified with hydrochloric and then re-basified with ammonia. The volatiles were removed under reduced pressure and the residue purified (SiO₂, methanol:dichloromethane:ammonia 6:93:1 increasing to 8:91:1 as eluant). Further purification using SCX resin, washing with methanol and then eluting with 10% ammonia in methanol gave the title compound (13 mg).

25

30 ¹H NMR (400 MHz, d₆-DMSO) δ 8.54 (1H, t), 7.78 (1H, d), 7.54 (2H, d), 7.38 (1H, d), 4.42 (1H, d), 4.15 (1H, d), 3.23 - 3.16 (1H, m), 3.13 - 3.06 (1H, m), 3.04 (2H, d), 3.01 -

2.95 (2H, m), 2.84 - 2.77 (1H, m), 2.39 (2H, t), 2.03 - 1.95 (1H, m), 1.96 (3H, s), 1.81 - 1.73 (1H, m), 1.72 - 1.65 (3H, m), 1.65 - 1.54 (9H, m), 1.52 - 1.45 (2H, m)


MS: APCI(+ve) 525 (M+H⁺).

m.p. 176-189°C

5

Example 13

6-Chloro-2-[(3*S*)-3-[[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-piperidiny]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide



10

The title compound was prepared and purified as described in Example 6 (c) using 6-chloro-2-[(3*S*)-3-[(2-cyanoethyl)amino]-1-piperidiny]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (Example 12 (b)) (200 mg), trimethylsilylazide (117 μL), dibutyltin oxide (23 mg) and toluene (2 mL). Purification (SiO₂,

15 methanol:dichloromethane:ammonia 10:90:1 eluant) gave an oil which was further purified using SCX, washing with methanol and then eluting with 10% ammonia in methanol to afford the title compound (50 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.54 (1H, t), 7.80 (1H, d), 7.59 - 7.52 (2H, m), 7.39 (1H, d), 4.52 - 4.46 (1H, m), 4.18 - 4.11 (1H, m), 3.30 - 3.18 (3H, m), 3.12 - 3.01 (5H, m), 2.10 - 2.03 (1H, m), 1.96 (3H, s), 1.87 - 1.77 (1H, m), 1.73 - 1.54 (15H, m)

20


MS: APCI(+ve) 549 (M+H⁺).

m.p. 168-172°C

25

Example 14

6-Chloro-2-[(3*S*)-3-[methyl[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-pyrrolidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide



a) 6-Chloro-2-[(3*S*)-3-[(2-cyanoethyl)methylamino]-1-pyrrolidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

To 6-chloro-2-[(3*S*)-3-[(2-cyanoethyl)amino]-1-pyrrolidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (Example 6 (b)) (360 mg) in methanol (10 mL) was added paraformaldehyde (200 mg) followed by sodium triacetoxyborohydride (300 mg). The reaction was stirred for 2 h before additional paraformaldehyde (200 mg) and sodium triacetoxyborohydride (300 mg) was added. After 2 h the reaction was poured into sodium hydrogen carbonate solution and extracted three times with dichloromethane. The combined organics were washed once with water and dried over magnesium sulphate before being filtered and the solvent removed to afford the sub-title compound (380 mg). MS: APCI(+ve) 506 (M+H⁺).

b) 6-Chloro-2-[(3*S*)-3-[methyl[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-pyrrolidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide


The title compound was prepared and purified as described in Example 6 (c) using 6-chloro-2-[(3*S*)-3-[(2-cyanoethyl)methylamino]-1-pyrrolidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (Example 14 (a)) (380 mg), trimethylsilylazide (200 μ L), dibutyltin oxide (37 mg) and toluene (3 mL). Further purification using SCX, washing with methanol and then eluting with 10% ammonia in methanol afforded the title compound (181 mg).

^1H NMR (300 MHz, d_6 -DMSO) δ 8.54 (1H, t), 7.76 (1H, d), 7.57 (1H, d), 7.49 (1H, d), 7.00 (1H, d), 3.91 - 3.80 (1H, m), 3.79 - 3.67 (1H, m), 3.50 - 3.38 (1H, m), 3.28 - 3.10 (2H, m), 3.03 (2H, d), 2.97 - 2.88 (2H, m), 2.84 - 2.75 (2H, m), 2.30 (3H, s), 2.25 - 2.13 (1H, m), 1.96 (3H, s), 1.88 - 1.78 (1H, m), 1.73 - 1.53 (12H, m).

5 MS: APCI(+ve) 549 ($\text{M}+\text{H}^+$).

Example 15

4-[6-Chloro-5-[[2-tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl]amino]carbonyl]-2-quinolinyl]-1-piperazinepropanoic acid, methyl ester



10

a) 5-Bromo-2,6-dichloro-quinoline

2,6-Dichloroquinoline (30 g) and aluminium trichloride (60 g) were heated to 120°C with stirring under a nitrogen atmosphere. Bromine (9.2 mL) was added dropwise over 1 hour and the mixture was then stirred at 120°C for 1 hour before being cooled to room temperature. A methanol / deionised water mixture (150 mL, 1:1) was then slowly added and the mixture was concentrated *in vacuo*. Dichloromethane (500 mL) and deionised water (250 mL) were added, the layers were separated and the aqueous fraction was extracted with dichloromethane (2 x 250 mL). The combined organic extracts were washed with saturated aqueous sodium hydrogen carbonate (250 mL) before being dried, filtered and concentrated. Purification by chromatography (SiO_2 , isohexane: dichloromethane 7:3 as eluant) gave the sub-title compound as a solid (27 g).

15

^1H NMR (400 MHz, CDCl_3) δ 8.53 (1H, d), 7.94 (1H, d), 7.78 (1H, d), 7.50 (1H, d). MS: APCI(+ve) 276/278/280/282 ($\text{M}+\text{H}^+$).

25

b) 2,6-Dichloro-5-quinolinecarboxylic acid

To a stirred solution of 5-bromo-2,6-dichloro-quinoline (Example 15 (a)) (23 g) in tetrahydrofuran (300 mL) at 0°C was added *iso*-propylmagnesium chloride (2M in tetrahydrofuran, 42 mL) over 2 hours. CO₂ was bubbled through the solution for 20 minutes and then methanol (20 mL) was added. The mixture was poured into water (500 mL) and extracted with ethyl acetate. The aqueous layer was acidified with hydrochloric acid (2M in water) to pH2-3 and the resulting solid collected by filtration. The solid was washed with water and dried to afford the sub-titled compound (11.5g).

¹H NMR (400 MHz, d₆-DMSO) δ 8.29 (1H, d), 8.07 (1H, d), 7.94 (1H, d), 7.74 (1H, d).

c) 2,6-Dichloro-*N*-(2-tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl)-5-quinolinecarboxamide

To 2,6-dichloro-5-quinolinecarboxylic acid (Example 15 (b)) (640 mg) in dichloromethane (5 mL) and *N,N*-dimethylformamide (1 drop) was added oxalyl chloride (500 µL) at 0°C over 2 minutes. The mixture was allowed to warm to room temperature and heated to 40°C for 30 minutes. Volatiles were removed under reduced pressure and the mixture redissolved in dichloromethane (5 mL). Tricyclo[3.3.1.1^{3,7}]decane-1-ethanamine (600 mg) and triethylamine (500 µL) in dichloromethane were added dropwise to the mixture which was stirred at room temperature for a further 2 h. The resulting white precipitate was collected by filtration and dried to afford the subtitled compound (410 mg).

MS: APCI(+ve) 402/404 (M+H⁺).

d) 6-Chloro-2-(1-piperaziny)-*N*-(2-tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl)-5-quinolinecarboxamide

To 2,6-dichloro-*N*-(2-tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl)-5-quinolinecarboxamide (Example 15 (c)) (220 mg) and triethylamine (500 µL) in acetonitrile (4 mL) was added piperazine (500 mg). The reaction was heated in a microwave at 120°C for 1 h and cooled to room temperature. The mixture was poured into aqueous sodium bicarbonate solution (10 mL) and extracted with dichloromethane (3 x 20 mL). The combined organic extracts were dried and purified by chromatography (SiO₂, methanol:dichloromethane 1:10 as eluant) to afford the subtitled compound as a solid (200 mg).

MS: APCI(+ve) 453.3 (M+H⁺).

e) 4-[6-Chloro-5-[[[(2-tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl)amino]carbonyl]-2-quinolinyl]-1-piperazinepropanoic acid, methyl ester


To 6-chloro-2-(1-piperazinyl)-*N*-(2-tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl)-5-quinolinecarboxamide (Example 15 (d)) (200 mg) in dichloromethane (7 mL) and triethylamine (500 μ L) at 0°C was added 2-propenoic acid, methyl ester (500 μ L). The mixture was stirred for 1 h and poured into aqueous sodium bicarbonate solution (10 mL) and extracted with dichloromethane (3 x 20 mL). The combined organic extracts were dried and purified by chromatography (SiO₂, methanol:dichloromethane 1:10 as eluant) to afford the title compound as a solid (120 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.54 (1H, t), 7.75 (1H, d), 7.58-7.48 (2H, m), 7.34 (1H, d), 3.68 (4H, m), 3.63 (3H, s), 3.37-3.28 (4H, m), 2.62 (2H, t), 2.56-2.47 (4H, m), 1.95 (3H, m), 1.74-1.59 (6H, m), 1.54 (6H, s), 1.36 (2H, dd).

MS: APCI(+ve) 539.0/541.0 (M+H⁺).

Example 16

4-[6-Chloro-5-[[[(2-tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl)amino]carbonyl]-2-quinolinyl]-1-piperazinepropanoic acid



Prepared by the method of Example 1(b) using 4-[6-chloro-5-[[[(2-tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl)amino]carbonyl]-2-quinolinyl]-1-piperazinepropanoic acid, methyl ester (Example 15 (e)) and sodium hydroxide (100 mg) in methanol (3 mL) and water (3 mL). The


mixture was acidified with aqueous hydrochloric acid, the resulting solid removed by filtration and dried to afford the title compound as a solid (60 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.57 (1H, t), 7.81 (1H, d), 7.60 (1H, d), 7.57 (1H, d), 7.40 (1H, d), 3.90 (4H, m), 3.32 (6H, m), 3.05 (2H, m), 2.71 (2H, t), 1.95 (3H, s), 1.76-1.59 (6H, m), 1.54 (6H, s), 1.37 (2H, m).

MS: APCI(+ve) 525.0/527.0 (M+H⁺).

Example 17

1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinolinyl]-4-hydroxy-4-piperidinecarboxylic acid



Prepared by the method of Example 3 using 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) and 4-hydroxy-4-piperidinecarboxylic acid, methyl ester (prepared as described in WO9910999) to afford the title compound (100 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 8.53 (1H, t), 7.78 (1H, d), 7.55 (1H, d), 7.52 (1H, d), 7.38 (1H, d), 4.27 (2H, m), 3.35 (2H, m), 3.03 (2H, d), 1.96 (3H, s), 1.86 (2H, dt), 1.73-1.54 (14H, m).

MS: APCI(+ve) 498/500 (M+H⁺).

m.p. 200-204°C

Example 18

1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]]dec-1-ylmethyl)amino]carbonyl]-2-quinolinyl]-4-phenyl-4-piperidinecarboxylic acid



5 To 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (250 mg), potassium carbonate (500 mg) in *N*-methyl pyrrolidinone (4 mL) was added 4-phenyl-4-piperidinecarboxylic acid, *p*-toluenesulfonate (800 mg). The resulting mixture was heated to 100°C for 18 h and then cooled to room temperature. The mixture was poured into water and extracted with dichloromethane (3 x
10 20 mL). The combined organic extracts were dried and concentrated to yield a solid which was recrystallised from ethyl acetate / methanol to give the title compound as a solid (100 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 8.69 (1H, s), 7.92 (1H, d), 7.77 (1H, m), 7.64 (1H, m),
15 7.48-7.35 (5H, m), 7.32-7.25 (1H, m), 4.60-4.39 (2H, m), 3.53-3.40 (2H, m), 3.05 (2H, d), 2.59 (2H, d), 2.10-1.92 (2H, m), 1.96 (3H, m), 1.73-1.52 (12H, m).

MS: APCI(-ve) 556/558 (M-H⁺).

m.p. 235-237°C

20 Example 19

(1*R*,5*S*)-3-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]]dec-1-ylmethyl)amino]carbonyl]-2-quinolinyl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid



Prepared by the method of Example 3 using 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (250 mg) and (1*R*,5*S*)-3-azabicyclo[3.1.0]hexane-6-carboxylic acid, 1,1-dimethylethyl ester (300 mg). The mixture was evaporated to an oil and treated with trifluoroacetic acid (2.5 mL) in dichloromethane (2.5 mL). After 3 h the mixture was evaporated to an oil and purified by HPLC (Symmetry - 0.1% aqueous ammonium acetate / acetonitrile) to afford the title product (120 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 8.54 (1H, t), 7.76 (1H, d), 7.53 (1H, d), 7.51 (1H, d), 6.96 (1H, d), 3.87 (2H, d), 3.56 (2H, d), 3.03 (2H, d), 2.10 (2H, s), 1.96 (3H, s), 1.72-1.58 (6H, m), 1.57 (6H, d), 1.32 (1H, t).

MS: APCI(-ve) 478/480 (M-H⁺).

m.p. 175-180°C

Example 20

6-Chloro-2-[4-[[[(methylsulfonyl)amino]carbonyl]-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide



a) 1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid monosodium salt

The sub-title compound was prepared as described in Example 5. Isolation of the sodium salt was achieved by treatment of the crude product in methanol with sodium hydroxide. After 12 h the resulting solid was filtered and washed with acetonitrile.

MS: APCI(+ve) 482 (M+H⁺).

b) 6-Chloro-2-[4-[[[(methanesulfonyl)amino]carbonyl]-1-piperidiny]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

To 1-[6-chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid monosodium salt (150 mg) (Example 20 (a)) and HATU (226 mg) in dichloromethane (5 mL) was added sulfamide (57 mg). The reaction was stirred for two hours and then dimethylaminopyridine (37 mg) in tetrahydrofuran (10 mL) added. After 12 hours the solvent was removed under vacuum with the resulting material being taken up in methanol (10 mL) and purified by HPLC (Symmetry - 0.1% aqueous ammonium acetate / acetonitrile) to afford the title compound (27 mg).


¹H NMR (300 MHz, d₆-DMSO) δ 8.53 (1H, t), 7.77 (1H, d), 7.58 - 7.49 (2H, m), 7.36 (1H, d), 4.48 (2H, d), 3.03 (2H, d), 2.99 (3H, s), 2.99 - 2.93 (2H, m), 2.46 - 2.37 (1H, m), 1.96 (3H, s), 1.88 - 1.78 (2H, m), 1.73 - 1.44 (14H, m)

MS: APCI(+ve) 559 (M+H⁺).

m.p. 170-173°C

Example 21

6-chloro-2-[4-[(hydroxyamino)carbonyl]-1-piperidinyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide



5

To 1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid monosodium salt (130 mg) (Example 20 (a)), triethylamine (72 μ L) and PyBroP (240 mg) in dichloromethane (5 mL) was added hydroxylamine solution (50%w/v in water (100 μ L)). The reaction was stirred for 2 h and ethanol (5 mL) added.

10

After 1 h the solvent was removed under vacuum with the resulting material being dissolved in methanol (10 mL) and purified by prep HPLC (Symmetry - 0.1% aqueous ammonium acetate / acetonitrile) to afford the title compound (49 mg).

15

¹H NMR (400 MHz, d₆-DMSO) δ 10.48 (1H, s), 8.72 (1H, s), 8.53 (1H, t), 7.78 (1H, d), 7.54 (2H, q), 7.37 (1H, d), 4.56 (2H, d), 3.04 (2H, d), 2.96 (2H, t), 2.38 - 2.29 (1H, m), 1.96 (3H, s), 1.74 - 1.51 (16H, m)


MS: APCI(+ve) 497 (M+H⁺).

m.p. 189-196°C

20

Example 22

6-Chloro-2-[4-(1H-1,2,4-triazol-3-ylsulfonyl)-1-piperidinyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide



a) 6-Chloro-2-(4-hydroxy-1-piperidinyl)-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

To 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (500 mg) and triethylamine (536 μ L) in acetonitrile (2 mL) was added 4-piperidinol (195 mg). The mixture was heated in a microwave for 4 h at 130°C and then cooled to room temperature. The resulting precipitate was filtered and washed with acetonitrile to afford the sub-titled compound (543 mg).

MS: APCI(+ve) 454 (M+H⁺).

b) 6-Chloro-2-[4-[(methylsulfonyl)oxy]-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

To 6-chloro-2-(4-hydroxy-1-piperidiny)-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (543 mg) (Example 22 (a)) and methanesulfonyl chloride (185 μ L) in dichloromethane (10 mL) was added triethylamine (333 μ L). The reaction was stirred for 12 h, poured onto a saturated solution of sodium hydrogen carbonate which was subsequently extracted with dichloromethane. The combined organics were washed with water, brine and the solvent removed to afford the sub-titled compound (770 mg).

MS: APCI(+ve) 532 ($M+H^+$).

c) 6-Chloro-2-[4-(1*H*-1,2,4-triazol-3-ylthio)-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide

To 6-chloro-2-[4-[(methylsulfonyl)oxy]-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (200 mg) (Example 22 (b)) and potassium carbonate (104 mg) in acetone (2 mL) and water (0.3 mL) was added 1*H*-1,2,4-triazole-3-thiol (57 mg). The mixture was heated in a microwave for 40 minutes at 120°C and then cooled to room temperature. The solvent was removed under vacuum and the reaction worked up as described in (Example 22 (b)) to afford the sub-titled compound (220 mg).

MS: APCI(+ve) 538/540 (M+H⁺).

d) 6-Chloro-2-[4-(1*H*-1,2,4-triazol-3-ylsulfonyl)-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide


Sodium tungstate (3 mg) was added to 6-chloro-2-[4-(1*H*-1,2,4-triazol-3-ylthio)-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (220 mg) (Example 22 (c)) dissolved in acetonitrile (30 mL) and water (3 mL). After 5 minutes hydrogen peroxide (35% solution) (300 µL) was added and stirred for 12 h whereupon additional hydrogen peroxide (300 µL) was added. After 12 h the volatiles were partially removed under vacuum and the residue purified by HPLC (Symmetry - 0.1% aqueous ammonium acetate / acetonitrile) to afford the title compound (58 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.53 (1H, t), 8.07 (1H, s), 7.78 (1H, d), 7.54 (2H, q), 7.36 (1H, d), 4.61 (2H, d), 3.64 - 3.48 (1H, m), 3.03 (2H, d), 3.04 - 2.94 (2H, m), 1.96 (3H, s), 1.97 - 1.91 (2H, m), 1.76 - 1.48 (14H, m).

MS: APCI(+ve) 569 (M+H⁺).

Example 23

2-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinolinyl]-benzoic acid



To 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO200308579) (200 mg) in tetrahydrofuran (1 mL) and water (1 mL) was added *tetrakis*(triphenylphosphine)palladium (10 mg), sodium carbonate (109 mg) and 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzoic acid ethyl ester (142 mg). The mixture was heated in a microwave for 120 minutes at 110°C and then cooled to room temperature. Sodium hydroxide solution (48%w/v) (500 µL) and methanol (2 mL) were added to the reaction which was then heated in a microwave at 70°C for 1 h. The solvent was removed under vacuum and the reaction acidified with 2M hydrochloric acid.

Removal of volatiles under vacuum was followed by dissolution in methanol and purification by HPLC (Symmetry - 0.1% trifluoroacetic acid / acetonitrile) to afford the title compound (115 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.72 (1H, t), 8.15 (1H, d), 8.01 (1H, d), 7.84 (3H, dd), 7.71 - 7.66 (2H, m), 7.63 - 7.56 (1H, m), 3.10 (2H, d), 1.97 (3H, s), 1.74 - 1.56 (12H, m).


MS: APCI(+ve) 475 (M+H⁺).

m.p. 156-158 °C

Example 24

3-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinolinyl]-benzoic acid

68



The title compound was prepared as described in Example 23 using 3-borono-benzoic acid methyl ester (92 mg). The compound was purified by HPLC (Symmetry - 0.1% aqueous ammonium acetate / acetonitrile) to afford the title compound (50 mg).


^1H NMR (300 MHz, d_6 -DMSO) δ 13.21 (1H, s), 8.86 (1H, s), 8.75 - 8.66 (1H, m), 8.52 (1H, d), 8.37 (1H, d), 8.24 (1H, d), 8.17 (1H, d), 8.10 (1H, d), 7.86 (1H, d), 7.71 (1H, t), 3.11 (2H, d), 1.98 (3H, s), 1.76 - 1.55 (12H, m).

MS: APCI(-ve) 473 (M-H^+).

m.p. 297-298 °C

Example 25

4-[6-Chloro-5-[[tricyclo[3.3.1.1.^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-benzoic acid



The title compound was prepared as described in Example 23 using 4-borono-benzoic acid methyl ester (92 mg). The compound was purified by HPLC (Symmetry - 0.1% aqueous trifluoroacetic acid/ acetonitrile) to afford the title compound (10 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 13.14 (1H, s), 8.73 - 8.68 (1H, m), 8.42 (2H, d), 8.37 (1H, d), 8.24 (1H, d), 8.17 - 8.09 (2H, m), 7.87 (1H, d), 3.10 (2H, d), 1.98 (3H, s), 1.73 - 1.57 (12H, m).

MS: APCI(+ve) 475 (M-H⁺).

m.p. 316-317 °C

Example 26

1-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinolinyl]-4-methyl-4-piperidinecarboxylic acid




Prepared by the method of Example 3 using 2,6-dichloro-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) and ethyl 4-methyl-piperidine-4-carboxylate hydrochloride (the product of treatment of ethyl N-boc-4-methyl-4-piperidine carboxylate (prepared as described in WO9925685) with HCl/CH₂Cl₂ and concentrating in vacuo) followed by purification by preparative HPLC to afford the title compound (15 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.26 (1H, s), 7.86 (1H, d), 7.73 (1H, d), 7.59 (1H, d), 7.40 (1H, d), 4.08 (2H, dt), 3.53-3.43 (2H), 3.06 (2H, d), 2.09 (2H, d), 1.97 (3H, s), 1.76-1.46 (14H, m), 1.22 (3H, s).

MS: APCI(+ve) 496 (M+H⁺).

Example 27

***N*-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]- β -alanine**




Prepared by the method of Example 2 using 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO2003080579) (250mg), β -alanine 1,1-dimethylethyl ester hydrochloride (1g) and triethylamine (0.9ml), heating for 200 minutes at 140°C. Further purification by recrystallisation from methanol gave the title compound (66mg).

¹H NMR (400 MHz, d₆-DMSO) δ 12.22 (1H, s), 8.50 (1H, t), 7.63 (1H, d), 7.49 (2H, dd), 7.30 (1H, t), 6.85 (1H, d), 3.59 (2H, dd), 3.02 (2H, d), 2.57 (2H, t), 1.95 (3H, s), 1.73 - 1.53 (12H, m).

MS: APCI(+ve) 442 (M+H⁺).
m.p. 251-252°C.

Example 28

5-[6-Chloro-5-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-3-pyridinecarboxylic acid



To 2,6-dichloro-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide (prepared as described in WO200308579) (200 mg) in tetrahydrofuran (2 mL) and water (1 mL) was added *tetrakis*(triphenylphosphine)palladium (40 mg), sodium carbonate (652 mg), 5-bromo-3-pyridinecarboxylic acid (333mg) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (390 mg). The mixture was heated in a microwave for 150 minutes at 150°C and then cooled to room temperature. Water was added to the reaction mixture which was subsequently extracted 4 times with dichloromethane. The combined organics were washed with brine, dried over magnesium sulfate, filtered and concentrated *in vacuo*. The crude product was dissolved in methanol and loaded onto a Varian NH₂ cartridge, washed with methanol and was eluted using 10% acetic acid in methanol. Further purification by preparative HPLC (Symmetry - 0.1% aqueous trifluoroacetic acid / acetonitrile) gave the title compound (21 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 9.67 (1H, d), 9.20 (1H, d), 9.10 (1H, t), 8.75 (1H, t), 8.49 (1H, d), 8.26 (1H, d), 8.20 (1H, d), 7.90 (1H, d), 3.11 (2H, d), 1.98 (3H, s), 1.73 - 1.58 (12H, m).

MS: APCI(-ve) 474 (M-H⁺).

m.p. 247°C.

Pharmacological Analysis

Certain compounds such as benzoylbenzoyl adenosine triphosphate (bbATP) are known to be agonists of the P2X₇ receptor, effecting the formation of pores in the plasma membrane (Drug Development Research (1996), 37(3), p.126). Consequently, when the receptor is activated using bbATP in the presence of ethidium bromide (a fluorescent DNA probe), an


increase in the fluorescence of intracellular DNA-bound ethidium bromide is observed. The increase in fluorescence can be used as a measure of P2X₇ receptor activation and therefore to quantify the effect of a compound on the P2X₇ receptor.

- 5 In this manner, each of the title compounds of the Examples was tested for antagonist activity at the P2X₇ receptor. Thus, the test was performed in 96-well flat bottomed microtitre plates, the wells being filled with 250 µl of test solution comprising 200 µl of a suspension of THP-1 cells (2.5×10^6 cells/ml) containing 10^{-4} M ethidium bromide, 25 µl of a high potassium buffer solution containing 10^{-5} M bbATP, and 25 µl of the high
- 10 potassium buffer solution containing concentrations of test compound typically from 30 µM – 0.001 µM. The plate was covered with a plastics sheet and incubated at 37 °C for one hour. The plate was then read in a Perkin-Elmer fluorescent plate reader, excitation 520 nm, emission 595 nm, slit widths: Ex 15 nm, Em 20 nm. For the purposes of comparison, bbATP (a P2X₇ receptor agonist) and pyridoxal 5-phosphate (a P2X₇ receptor
- 15 antagonist) were used separately in the test as controls. From the readings obtained, a pIC₅₀ figure was calculated for each test compound, this figure being the negative logarithm of the concentration of test compound necessary to reduce the bbATP agonist activity by 50%. Each of the compounds of the Examples demonstrated antagonist activity, having a pIC₅₀ figure > 5.0. For example, the following table shows the pIC₅₀
- 20 figures for a representative selection of compounds:

| Compound of Example No. | pIC ₅₀ |
|-------------------------|-------------------|
| 3 | 7.1 |
| 12 | 7.8 |
| 13 | 7.6 |
| 24 | 7.2 |

CLAIMS

1. A compound of formula



or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, wherein
n represents 1, 2 or 3;

each R^1 independently represents hydrogen, hydroxy or a halogen;

10 A is C(O)NH or NHC(O);

p is 0, 1 or 2;

each R^2 independently represents halogen or C_{1-6} alkyl optionally substituted by at least
one substituent independently selected from hydroxyl, halogen and C_{1-6} alkoxy;

q is 0, 1 or 2;

15 each R^4 independently represents halogen or C_{1-6} alkyl optionally substituted by at least
one substituent independently selected from hydroxyl, halogen and C_{1-6} alkoxy;

R^3 represents a group Y^1R^6 or Z^1R^{10} ;

20 R^6 represents a group R^8 or a 4- to 9-membered carbocyclic or heterocyclic ring, which
carbocyclic or heterocyclic ring is substituted by at least one substituent independently
selected from Y^2R^9 and Z^2R^{11} , and which 4- to 9-membered carbocyclic or heterocyclic
ring may further be optionally substituted by at least one substituent independently selected
from halogen, hydroxyl, C_{1-6} alkoxy, C_{1-6} alkyl, phenyl and a 5- to 6-membered
25 heteroaromatic ring, which C_{1-6} alkyl, phenyl or 5- to 6-membered heteroaromatic ring may

be optionally substituted by at least one substituent selected from halogen, hydroxyl and C₁₋₆alkoxy;

R⁸ and R⁹ each independently represent tetrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl or a 5- to 6-membered heterocyclic ring comprising from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, which heterocyclic ring is substituted by at least one substituent selected from hydroxyl, =O and =S, and which heterocyclic ring may further be optionally substituted by at least one substituent selected from halogen, nitro, amino, cyano, C₁₋₆ alkylsulphonyl, C₁₋₆alkoxycarbonyl and a C₁₋₆ alkyl group which C₁₋₆ alkyl group can be optionally substituted by at least one substituent selected from halogen, hydroxyl and amino;

R¹⁰ and R¹¹ each independently represent carboxyl, C₁₋₆ alkylsulphonylaminocarbonyl, C(O)NHOH or NHR¹²; R¹² represents CN, C₁₋₆ alkylsulphonyl, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylaminosulphonyl or (di)-C₁₋₆ alkylaminosulphonyl;

Y¹ and Y² each independently represent a bond, O, S(O)₀₋₂, NR⁷C(O), C(O)NR⁷, SO₂NR⁷, NR⁷SO₂, >NR⁷, O(CH₂)₁₋₆, S(O)₀₋₂(CH₂)₁₋₆, NR⁷(CH₂)₁₋₆, (CH₂)₁₋₃O(CH₂)₁₋₃, (CH₂)₁₋₃S(O)₀₋₂(CH₂)₁₋₃, (CH₂)₁₋₃NR⁷(CH₂)₁₋₃, (CH₂)₁₋₃NR⁷C(O)(CH₂)₀₋₃, (CH₂)₁₋₃C(O)NR⁷(CH₂)₀₋₃, S(O)₀₋₂(CH₂)₁₋₆NR⁷ or a C₁₋₆ alkylene which C₁₋₆ alkylene can be optionally substituted by at least one substituent independently selected from hydroxyl, halogen and C₁₋₆alkoxy;

Z¹ and Z² each independently represent a bond, O(CH₂)₁₋₆, S(O)₀₋₂(CH₂)₁₋₆, NR⁷(CH₂)₁₋₆, (CH₂)₁₋₃O(CH₂)₁₋₃, (CH₂)₁₋₃S(O)₀₋₂(CH₂)₁₋₃, (CH₂)₁₋₃NR⁷(CH₂)₁₋₃, (CH₂)₁₋₃NR⁷C(O)(CH₂)₁₋₃, (CH₂)₁₋₃C(O)NR⁷(CH₂)₁₋₃ or a C₁₋₆ alkylene which C₁₋₆ alkylene can be optionally substituted by at least one substituent independently selected from hydroxyl, halogen and C₁₋₆alkoxy; and

each R⁷ independently represents hydrogen or a C₁₋₆ alkyl group which can be optionally substituted by at least one substituent independently selected from hydroxyl, halogen and C₁₋₆alkoxy;

with the provisos that:-

- (a) when R^3 represents Y^1R^6 and Y^1 represents $NR^7(CH_2)_{1-6}$, $S(CH_2)_{1-6}$, $O(CH_2)_{1-6}$ or an optionally substituted C_{1-6} alkylene, then R^6 does not represent oxopyrrolidinyl;
- (b) when R^3 represents Z^1R^{10} and Z^1 represents $(CH_2)_{1-3}NR^7(CH_2)_{1-3}$, then R^{10} does not represent carboxyl;
- (c) when R^3 represents Y^1R^6 and Y^1 represents $(CH_2)_{1-3}NR^7(CH_2)_{1-3}$ and R^6 represents a group R^8 then R^8 does not represent a 5- to 6-membered heterocyclic ring substituted by hydroxyl or =O;
- (d) when R^3 represents Y^1R^6 and Y^1 represents $(CH_2)_{1-3}NR^7(CH_2)_{1-3}$ and R^6 represents a 4- to 9-membered carbocyclic or heterocyclic ring substituted by Z^2R^{11} and Z^2 represents a bond, then R^{11} does not represent carboxyl;
- (e) when R^3 represents Y^1R^6 and Y^1 represents $NR^7(CH_2)_{1-6}$, $S(CH_2)_{1-6}$, $O(CH_2)_{1-6}$ or an optionally substituted C_{1-6} alkylene and R^6 represents phenyl substituted by Z^2R^{11} and Z^2 represents a bond, then R^{11} does not represent C_{1-6} alkylsulphonylamino;
- (f) when R^3 represents Z^1R^{10} and Z^1 represents $O(CH_2)_{1-6}$, $S(CH_2)_{1-6}$, $NR^7(CH_2)_{1-6}$ or an optionally substituted C_{1-6} alkylene and R^{10} represents NHR^{12} , then R^{12} does not represent C_{1-6} alkylcarbonyl; and
- (g) the compound is not selected from tert-butyl 1-{5-[(1-adamantylacetyl)amino]-6-methylquinolin-2-yl}piperidin-4-ylcarbamate and tert-butyl (3S)-1-{5-[(1-adamantylacetyl)amino]-6-methylquinolin-2-yl}pyrrolidin-3-ylcarbamate.

2. A compound according to claim 1, wherein A represents $C(O)NH$.

3. A compound according to claim 1 or claim 2, wherein R^{10} and R^{11} each independently represent carboxyl, C_{1-6} alkylsulphonylaminocarbonyl or $C(O)NHOH$.

4. A compound according to any one of claims 1 to 3, wherein R^3 represents a group Y^1R^6 .

5. A compound according to any one of claims 1 to 4, wherein Y^1 represents a bond.

6. A compound according to any one of claims 1 to 5, wherein R⁶ represents an aliphatic 5- to 8-membered heterocyclic ring containing one nitrogen atom and optionally one further heteroatom selected from nitrogen and oxygen.

7. A compound according to claim 1, which is selected from

1-[6-Chloro-5-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylacetyl)amino]-2-quinoliny]-
4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-
D-proline,

1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-
(3*R*)-3-piperidinecarboxylic acid,

6-Chloro-2-[4-(1,5-dihydro-5-oxo-4*H*-1,2,4-triazol-4-yl)-1-piperidinyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

4-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-1-
piperazineacetic acid,

6-Chloro-2-[(3*S*)-3-[[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-pyrrolidinyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-
4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-quinoliny]-
4-piperidineacetic acid,

6-Chloro-2-[4-(2*H*-tetrazol-5-yl)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-
quinolinecarboxamide,

6-Chloro-2-[4-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)butyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

N-[(3*S*)-1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-
quinoliny]-3-pyrrolidinyl]-β-alanine,

N-[(3*S*)-1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]-2-
quinoliny]-3-piperidinyl]-β-alanine,

6-Chloro-2-[(3*S*)-3-[[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-piperidinyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

6-Chloro-2-[(3*S*)-3-[methyl[2-(2*H*-tetrazol-5-yl)ethyl]amino]-1-pyrrolidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

4-[6-Chloro-5-[[2-(tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl)amino]carbonyl]-2-quinoliny]-1-piperazinepropanoic acid,

1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-4-hydroxy-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-4-phenyl-4-piperidinecarboxylic acid,

(1*R*,5*S*)-3-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid,

6-Chloro-2-[4-[[methylsulfonyl]amino]carbonyl]-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

6-Chloro-2-[4-[(hydroxyamino)carbonyl]-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

6-Chloro-2-[4-(1*H*-1,2,4-triazol-3-ylsulfonyl)-1-piperidinyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-quinolinecarboxamide,

2-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-benzoic acid,

3-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-benzoic acid,

4-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-benzoic acid,

1-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-4-methyl-4-piperidinecarboxylic acid,


N-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-β-alanine,

5-[6-Chloro-5-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]-2-quinoliny]-3-pyridinecarboxylic acid,


or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

8. A process for the preparation of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, which comprises either:

(a) reacting a compound of formula (III)




wherein L^1 represents a leaving group (e.g. hydroxyl or halogen) and R^2 , R^3 , R^4 , p and q are as defined in formula (I), with a compound of formula (IV),




wherein R^1 and n are as defined in formula (I); or

(b) reacting a compound of formula (V)



wherein R^2 , R^3 , R^4 , p and q are as defined in formula (I), with a compound of formula (VI)

79




(VI)

wherein L^2 represents a leaving group (e.g. hydroxyl or halogen) and R^1 and n are as defined in formula (I); or

5

(c) when R^3 represents a group Y^1R^6 or Z^1R^{10} wherein the atom directly attached to the quinoline group of formula (I) is a nitrogen atom, reacting a compound of formula (VII)




(VII)

10

wherein L^3 is a leaving group (e.g. halogen, paratoluene sulphonate or methane sulphonate), and all other variables are as defined in relation to formula (I), with a compound of formula (VIII), $H-NY^{1''}R^{6''}$ or formula (IX), $H-NZ^{1''}R^{10''}$ wherein $NY^{1''}R^{6''}$ or $NZ^{1''}R^{10''}$ make up a group of Y^1R^6 or Z^1R^{10} respectively as defined in formula (I); or

15


(d) when R^3 represents a group Y^1R^6 or Z^1R^{10} wherein the group directly attached to the quinoline group of formula (I) is CH_2CH_2 , reacting a compound of formula (VII) as defined in (c) above with a compound of formula (X), (XI), (XII) or (XIII)



20

wherein $Y^{1'}R^{6'}$ and $Z^{1'}R^{10'}$ are suitably defined such that reaction of (VII) with (X), (XI), (XII) or (XIII) and subsequent hydrogenation of any resulting alkene or alkyne yields a compound wherein R^3 represents a group Y^1R^6 or Z^1R^{10} ; or

- 5 (e) when R^3 represents a group Y^1R^6 or Z^1R^{10} wherein the group directly attached to the quinoline group of formula (I) is CH_2CH_2N , reacting a compound of formula (VII) as defined in (c) above with a compound of formula (XIV)




- 10 wherein L^4 is a leaving group (eg. trialkyltin, dialkylboron or zinc), followed by reaction with a compound of formula (XV), $HNY^{1'''}R^{6'''}$ or (XVI) $HZ^{1'''}R^{10'''}$, wherein $NY^{1'''}R^{6'''}$ or $NZ^{1'''}R^{10'''}$ make up a group of Y^1R^6 or Z^1R^{10} respectively as defined in formula (I);

- 15 (f) when R^3 represents a group Y^1R^6 or Z^1R^{10} wherein the group directly attached to the quinoline group of formula (I) is CH_2N , reacting a compound of formula (VII) as defined in (c) above with a compound of formula (XIV) as defined in (e) above, followed by an oxidation reaction and then by reaction with a compound of formula (XV) or (XVI) as defined in (e) above under reductive amination conditions; or

- 20 (g) when R^3 represents a group Y^1R^6 or Z^1R^{10} wherein the group directly attached to the quinoline group of formula (I) is CH_2CH_2 , reacting a compound of formula (VII) as defined in (c) above with a compound of formula (XII) or (XIII) as defined above wherein $Y^{1'}R^{6'}$, $Z^{1'}R^{10'}$ are suitably defined such that saturation of the alkene and subsequent combination with a compound of formula (VII) yields a compound wherein R^3 represents a group Y^1R^6 or Z^1R^{10} ; or


25

- (h) when R^8 or R^9 represent a tetrazole, reacting a compound of formula




wherein R^{6a} is 4- to 9- membered carbocyclic or heterocyclic ring and all other variables are as defined in relation to formula (I), with a compound of formula PN_3 wherein P is sodium, a trialkylsilyl, an alkyltin or ammonium; or

(i) when R^8 or R^9 represent a group of formula (XVII)




reacting a compound of formula (XXIII) or (XXIV) as defined above in (h) with hydroxylamine, followed by treatment with 1,1'-thiocarbonyldiimidazole and subsequent treatment with silica to yield a compound wherein R^8 or R^9 represent a group of formula (XVII) wherein J is S; alternatively reacting a compound of formula (XXVII) or (XXVIII) with hydroxylamine, followed by treatment with a chloroformate to yield a compound wherein R^8 or R^9 represent a group of formula (XVII) wherein J is O; or

(j) when R^8 or R^9 represent a group of formula (XVIII)




reacting a compound of formula




wherein R^{6a} is 4- to 9- membered carbocyclic or heterocyclic ring and all other variables are as defined in relation to formula (I), with phosgene or a phosgene equivalent followed by treatment with formyl hydrazine and subsequent treatment with base; or

(k) when R^8 or R^9 represent a group of formula (XIX)



reacting a compound of formula (XXV) or (XXVI) as defined above in (j) with ethyl chloroacetate, followed by reaction with (chlorosulfonyl)-carbamic acid, 1,1-dimethylethyl ester and subsequent treatment with acid and base to yield a compound wherein R^8 or R^9 represent a group of formula (XIX); or


(l) when R_3 represents a group Y^1R^6 wherein Y^1 is a bond and R^6 is an aromatic carbocyclic or heterocyclic ring substituted by carboxyl, reacting a compound of formula (VII) as defined in (c) above with a compound of formula (XXVII)



wherein M represents an organoboron group such as $B(OH)_2$, $B(O^iPr)_2$, BEt_2 or a boronic acid pinacol cyclic ester and R^{6b} represents an aromatic carbocyclic or heterocyclic

ring substituted by carboxyl or CO₂C₁₋₆alkyl, optionally followed by reaction with a base such; or

(m) when R₃ represents a group Y¹R⁶ wherein Y¹ is a bond and R⁶ is an aromatic carbocyclic or heterocyclic ring substituted by carboxyl, reacting a compound of formula (VII) as defined in (c) above with a compound of formula (XXVIII)



wherein L⁴ represents a leaving group and R^{6c} represents an aromatic carbocyclic or heterocyclic ring substituted by carboxyl, in the presence of a diboron compound;

and optionally after (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) or (m) carrying out one or more of the following:

- converting the compound obtained to a further compound of the invention
- forming a pharmaceutically acceptable salt of the compound
- forming an *in vivo* hydrolysable ester of the compound.

9. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 7 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

10. A process for the preparation of a pharmaceutical composition as claimed in claim 9 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as defined in any one of claims 1 to 7 with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. A compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 7 for use in therapy.

12. Use of a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 7 in the manufacture of a medicament for use in the treatment of rheumatoid arthritis.

13. Use of a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 7 in the manufacture of a medicament for use in the treatment of osteoarthritis.

14. Use of a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 7 in the manufacture of a medicament for use in the treatment of asthma or chronic obstructive pulmonary disease.

15. Use of a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 7 in the manufacture of a medicament for use in the treatment of atherosclerosis.

16. A method of treating rheumatoid arthritis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 7.

17. A method of treating osteoarthritis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 7.

18. A method of treating an obstructive airways disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a

pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 7.

19. A method of treating atherosclerosis which comprises administering to a patient a
5 therapeutically effective amount of a compound of formula (I), or a pharmaceutically
acceptable salt or an *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to
7.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2005/001782

A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM. ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| X | WO 03080579 A1 (ASTRAZENECA AB), 2 October 2003 (02.10.2003) -- | 1-15 |
| A | WO 03042190 A1 (PFIZER PRODUCTS INC.), 22 May 2003 (22.05.2003) -- | 1-19 |
| A | WO 0194338 A1 (ASTRAZENECA AB), 13 December 2001 (13.12.2001) -- | 1-19 |
| A | WO 0061569 A1 (ASTRAZENECA AB), 19 October 2000 (19.10.2000) -- | 1-19 |

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

1 February 2006

Date of mailing of the international search report

06-02-2006

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Eva Johansson/EK

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2005/001782

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 16-19
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 16-19 relate to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic
.../...
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

Box II.1

methods /Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2005/001782

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A | WO 9929660 A1 (ASTRA AKTIEBOLAG), 17 June 1999 (17.06.1999) ----- | 1-19 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2005/001782

INTERNATIONAL PATENT CLASSIFICATION (IPC):

C07D 401/04 (2006.01)
A61K 31/47 (2006.01)
A61K 31/4709 (2006.01)
A61K 31/496 (2006.01)
A61P 11/06 (2006.01)
A61P 19/02 (2006.01)
A61P 19/08 (2006.01)
A61P 9/10 (2006.01)
C07D 215/14 (2006.01)
C07D 215/38 (2006.01)
C07D 401/06 (2006.01)
C07D 401/14 (2006.01)
C07D 413/06 (2006.01)

INTERNATIONAL SEARCH REPORT

Information on patent family members

26/11/2005

International application No.

PCT/SE 2005/001782

| | | | | | | | |
|-------|----------|----|------------|----|-------------|-----|------------|
| WO | 03080579 | A1 | 02/10/2003 | AU | 2003216013 | A | 00/00/0000 |
| | | | | EP | 1399103 | A | 24/03/2004 |
| | | | | EP | 1490341 | A | 29/12/2004 |
| | | | | JP | 2004527322 | T | 09/09/2004 |
| | | | | JP | 2005528363 | T | 22/09/2005 |
| | | | | SE | 0200920 | D | 00/00/0000 |
| | | | | US | 20040134103 | A | 15/07/2004 |
| | | | | US | 20050090524 | A | 28/04/2005 |
| ----- | | | | | | | |
| WO | 03042190 | A1 | 22/05/2003 | AT | 302196 | T | 15/09/2005 |
| | | | | BR | 0204588 | A | 16/09/2003 |
| | | | | CA | 2411544 | A | 12/05/2003 |
| | | | | DE | 60205564 | D | 00/00/0000 |
| | | | | EP | 1310493 | A,B | 14/05/2003 |
| | | | | JP | 2003183263 | A | 03/07/2003 |
| | | | | MX | PA02009783 | A | 21/05/2003 |
| | | | | US | 6927219 | B | 09/08/2005 |
| | | | | US | 20030144293 | A | 31/07/2003 |
| ----- | | | | | | | |
| WO | 0194338 | A1 | 13/12/2001 | AU | 6447401 | A | 17/12/2001 |
| | | | | EP | 1292590 | A | 19/03/2003 |
| | | | | GB | 0013737 | D | 00/00/0000 |
| | | | | JP | 2004506611 | T | 04/03/2004 |
| | | | | US | 6949539 | B | 27/09/2005 |
| | | | | US | 20030187031 | A | 02/10/2003 |
| ----- | | | | | | | |

INTERNATIONAL SEARCH REPORT
Information on patent family members

26/11/2005

International application No.

PCT/SE 2005/001782

WO 0061569 A1 19/10/2000

| | | |
|----|--------------|------------|
| AU | 774526 B | 01/07/2004 |
| AU | 3994700 A | 14/11/2000 |
| AU | 5547000 A | 02/01/2001 |
| BR | 0009651 A | 08/01/2002 |
| CA | 2368829 A | 19/10/2000 |
| CN | 1147483 C | 28/04/2004 |
| CN | 1353702 A,T | 12/06/2002 |
| CZ | 20013608 A | 15/05/2002 |
| EE | 200100525 A | 16/12/2002 |
| EP | 1171432 A | 16/01/2002 |
| GB | 0002330 D | 00/00/0000 |
| HU | 0202214 A | 28/10/2002 |
| IL | 145505 D | 00/00/0000 |
| JP | 2002541249 T | 03/12/2002 |
| NO | 20014894 A | 10/12/2001 |
| NZ | 514477 A | 29/04/2003 |
| PL | 350907 A | 10/02/2003 |
| SK | 13422001 A | 09/05/2002 |
| TR | 200102911 T | 00/00/0000 |
| US | 6492355 B | 10/12/2002 |
| AP | 200102041 D | 00/00/0000 |
| AT | 250036 T | 15/10/2003 |
| AU | 751103 B | 08/08/2002 |
| AU | 4950499 A | 07/02/2000 |
| BR | 9912109 A | 02/05/2001 |
| CA | 2336968 A,C | 27/01/2000 |
| DE | 69911415 D,T | 08/07/2004 |
| DK | 1095021 T | 24/11/2003 |
| EE | 200100010 A | 17/06/2002 |
| EP | 1095021 A,B | 02/05/2001 |
| SE | 1095021 T3 | |
| HK | 1035715 A | 00/00/0000 |
| HR | 20010039 A | 31/12/2001 |
| HU | 0103224 A | 28/01/2002 |
| IL | 140346 D | 00/00/0000 |
| JP | 2002520395 T | 09/07/2002 |
| NO | 20010211 A | 15/03/2001 |
| NZ | 508923 A | 27/09/2002 |
| PL | 345388 A | 17/12/2001 |
| SE | 9901270 D | 00/00/0000 |
| UA | 64791 C | 15/03/2001 |
| ZA | 200108265 A | 08/01/2003 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

26/11/2005

International application No.

PCT/SE 2005/001782

| | | | | | | | |
|----|---------|----|------------|----|------------|-----|------------|
| WO | 9929660 | A1 | 17/06/1999 | AT | 234274 | T | 15/03/2003 |
| | | | | AU | 746716 | B | 02/05/2002 |
| | | | | AU | 1791499 | A | 28/06/1999 |
| | | | | BR | 9813368 | A | 03/10/2000 |
| | | | | CA | 2312889 | A | 17/06/1999 |
| | | | | CN | 1280560 | A,T | 17/01/2001 |
| | | | | DE | 69812159 | D,T | 18/12/2003 |
| | | | | DK | 1036058 | T | 30/06/2003 |
| | | | | EE | 200000320 | A | 15/08/2001 |
| | | | | EP | 1036058 | A,B | 20/09/2000 |
| | | | | SE | 1036058 | T3 | |
| | | | | ES | 2195433 | T | 01/12/2003 |
| | | | | HK | 1028594 | A | 00/00/0000 |
| | | | | HU | 0100431 | A | 30/07/2001 |
| | | | | IL | 136503 | D | 00/00/0000 |
| | | | | JP | 2001525391 | T | 11/12/2001 |
| | | | | NO | 20002785 | A | 01/08/2000 |
| | | | | NZ | 504375 | A | 29/08/2003 |
| | | | | PL | 340890 | A | 12/03/2001 |
| | | | | PT | 1036058 | T | 31/07/2003 |
| | | | | RU | 2197477 | C | 27/01/2003 |
| | | | | SE | 9704545 | D | 00/00/0000 |
| | | | | SK | 8412000 | A | 07/11/2000 |
| | | | | TR | 200001558 | T | 00/00/0000 |
| | | | | US | 6242470 | B | 05/06/2001 |
